Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
Sr. Clinical Program 
Manager: (rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate 
FITAF in HIV-1 Infected Subjects who are V irologically 
Suppressed on Regimens containing ABC/3TC 
[COMPANY_009] Sciences, Inc. 
[ADDRESS_893117] 
Foster City, CA 9440 
111851 
2015-000871-28 
Not Available 
HIV -1 Infection 
GS-US-311-1717 
Name: 
[CONTACT_10880]: 
Fax: [COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] I 
[COMPANY_009] Medical Monitor: Name: [CONTACT_662174], MD, MPH 
[COMPANY_003] Telephone: 
Mobile: [COMPANY_003] 
Fax: [COMPANY_003] 
Protocol Version/Date: Original: [ADDRESS_893118] or Independent Ethics Committee. The infonnation is only to be used by [CONTACT_580875]. 
You will not disclose any of the infonnation to others without written authorization from [COMPANY_009] 
Sciences, Inc., except to the extent necessruy to obtain infonned consent from those persons to 
whom the dmg m ay be administered. 
F/TAF
Protocol GS -US-311-[ADDRESS_893119] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 11
1.INTRODUCTION .............................................................................................................................................. 15
1.1.Background ............................................................................................................................................ 15
1.2.Emtricitabine/Tenofovir Alafenamide (F/TAF) ..................................................................................... 16
1.3.Tenofovir Alafenamide (TAF, GS 7340) ............................................................................................... 16
1.3.1. General Information ............................................................................................................. 16
1.3.2. Preclinical Pharmacology and Toxicology ........................................................................... 17
1.3.3. Nonclinical Pharmacokinetics .............................................................................................. 17
1.3.4. Nonclinical Toxicology ........................................................................................................ 18
1.3.5. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) 
or Fixed Dose Combination emtricitab ine/tenofovir alafenamide (F/TAF) ......................... 19
1.3.6. Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir 
Alafenamide (E/C/F/TAF) ................................................................................................... 21
1.3.7. Clinical Trials of Darunavir/Cobicistat/Emtricitabine/TAF (D/C/F/TAF) ........................... 25
1.4.Emtricitabine (FTC, Emtriva®) ............................................................................................................. 26
1.4.1. General Information ............................................................................................................. 26
1.5.Information about Fixed Dose Combination of Abacavir/Lamivudine (ABC/3TC, Epzicom, 
Kivexa)................................................................................................................................................. [ADDRESS_893120] Selection ............................................................................................ 35
4.2.Inclusion Criteria .................................................................................................................................... 35
4.3.Exclusion Criteria ................................................................
................................................................... 37
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 38
5.1.Randomization, Blinding and Treatment Codes .................................................................................... 38
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 38
5.2.Description and Handling ....................................................................................................................... 39
5.2.1. Formulation.......................................................................................................................... 39
5.2.2. Packaging and Labeling ....................................................................................................... 40
5.2.3. Storage and Handling ........................................................................................................... 40
5.3.Dosage and Administration .................................................................................................................... 41
F/TAF
Protocol GS -US-311-[ADDRESS_893121] (IMP) ........................................ [ADDRESS_893122] Enrollment and Treatment Assignment ..................................................................................... 45
6.2.Pretreatment Visit Assessments ............................................................................................................. 45
6.2.1. Screening Visit ..................................................................................................................... 45
6.2.2. Day 1 Visit........................................................................................................................... 46
6.3.Treatment Assessments .......................................................................................................................... 48
6.3.1. Treatment Visits (Weeks 4 –48).......................................................................................... 48
6.3.2. Treatment Visits (Weeks 60 -96).......................................................................................... 51
6.3.3. Treatment Visits (Post Week [ADDRESS_893123] 
Unblinding Visit) ................................................................................................................. [ADDRESS_893124]-treatment Assessments ................................................................................................................... 56
6.4.1. Early Study Drug Discontinuation (ESDD) Visit ................................................................. 56
6.4.2. 30 Day Follow -Up Visit....................................................................................................... 58
6.5.Criteria for Discontinuation of Study Treatment.................................................................................... 59
6.6.Bone Mineral Density Evaluations ......................................................................................................... 59
6.7.Other Evaluations ................................................................................................................................... 60
6.7.1. Markers of Bone Turnover ................................................................................................... 60
6.7.2. Markers of Renal Tubular Function ..................................................................................... 60
6.7.3. Markers of Inflammation ................................
...................................................................... 60
6.7.4. Markers of Platelet Function ................................................................................................ 60
6.8.Blood and Urine Storage ........................................................................................................................ 60
6.9.Virologic Failure .................................................................................................................................... 60
6.9.1. Management of Virologic Failure ........................................................................................ 61
6.9.2. Subjects with ≥ 400 copi[INVESTIGATOR_014]/mL of HIV -1 in the Absence of VR ......................................... 61
6.10.Platelet Function Substudy ..................................................................................................................... 63
7.ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 64
7.1.Definitions of Adverse Events, Ad verse Reactions, and Serious Adverse Events ................................. 64
7.1.1. Adverse Events ..................................................................................................................... 64
7.1.2. Serious Adverse Events ........................................................................................................ 64
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 65
7.2.Assessment of Adverse Events and Serious Adverse Events ................................................................. 65
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 65
7.2.2. Assessment of Severity ........................................................................................................ 66
7.3.Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to [COMPANY_009] ....................................................................................................................... 66
7.3.1. Adverse Events ..................................................................................................................... 66
7.3.2. Serious Adverse Events ........................................................................................................ 66
7.4.[COMPANY_009] Reporting Requirements ............................................................................................................. 67
7.5.Special Situations Reports ...................................................................................................................... 68
7.5.1. Definitions of Special Situations .......................................................................................... 68
7.5.2. Instructions for Reporting Special Situations ....................................................................... 69
7.6.Toxicity Management ............................................................................................................................ 70
7.6.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 70
7.6.2. Grades 3 Laboratory Abnormality or Clinical Event ........................................................... 70
7.6.3.Grade 4 Laboratory Abnormality or Clinical Event ............................................................. 71
7.6.4. Management of Bone Evaluation ......................................................................................... 71
F/TAF
Protocol GS -US-311-[ADDRESS_893125] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... [ADDRESS_893126] Accountability and Return ............................................. 83
9.1.8. Inspections ............................................................................................................................ 83
9.1.9. Protocol Compliance ............................................................................................................ 84
9.2.Sponsor Responsibilities ........................................................................................................................ 84
9.2.1. Protocol Modifications ......................................................................................................... 84
9.2.2. Study Report and Publications ............................................................................................. 84
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 84
9.3.1. Payment Reporting ............................................................................................................... 84
9.3.2. Access to Information for Monitoring .................................................................................. 85
9.3.3. Access to Information for Auditing or Inspections .............................................................. 85
9.3.4. Study Discontinuation .......................................................................................................... 85
10.REFERENCES ................................................................................................................................................... 86
11.APPENDICES .................................................................................................................................................... 88
Appendix 1.Investigator Signature [CONTACT_3490] .................................................................................................... 89
Appendix 2.Study Procedures Table .......................................................................................................... 90
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page5 11 March 2015Appendix 3.Management of Clinical and Laboratory Adverse Events ...................................................... 95
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 96
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Recommendations ......................................................................................... 119
Appendix 6.Definitions of HIV -1 Related Disease (CDC Guidelines) .................................................... [ADDRESS_893127] OF IN -TEXT TABLES
Table1-1. GS-US-311-0101, GS -US-120-0117, and GS -US-120-0118: Changes in TAF 
exposures when Coadministered w ith Third Agents .............................................................. 20
Table1-2. Dose Recommendations for F/TAF with Potential Concomitant Antiretroviral Drugs ..........29
Table3-1. Recommended F/TAF dose by [CONTACT_3252] -administered third agent: ................................................. 33
Table4
-1. Allowable Antiretroviral Agents of Pre -Existing Regimen .................................................... 36
Table5-1. Recommended F/TAF Dose by [CONTACT_15957] -administered Third Agent .............................................. [ADDRESS_893128] OF IN -TEXT FIGURES
Figure3-1.Study Schema ......................................................................................................................... 33
Figure6-1.Schema for Management of Virologic Failure ....................................................................... 62
F/TAF
Protocol GS -US-311-[ADDRESS_893129]
Foster City, CA [ZIP_CODE]
StudyTitle: A Phase 3b, Randomized, Double- Blind, Switch Study  to Evaluate 
F/TAF in HIV -1 InfectedSubjects who are Virologically  Suppressed 
on Regimens containing ABC/3TC
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:[PHONE_13692]-000871-28 
Not Available
Study Centers 
Planned:Approximately  100 centers in Europe and North America 
Objectives: The primary  objective is:
To evaluate the efficacy  of switching ABC/3TC to F/TAFversus 
maintaining ABC/3TC in HIV-1 infected subjects who are 
virologicall y suppressed on regimens containing ABC/3TC as 
determined b y the proportion of subjects with HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL at Week48 
The secondary  objectives are:
To evaluate the efficacy, safety and tolerability of two regimens
through Week 48 and Week 
96
To evaluate the bone safety  of two reg imens as determined by  [CONTACT_662157][INVESTIGATOR_662136] (BMD) through Week 48 and Week 96
Study Design: Randomized, double -blind, multicenter, active -controlled study  to 
evaluate the safet y and efficacy of switching ABC/3TC fixed-dose 
combination (FDC) tablet to F/TAF FDC tablet versus continuing 
ABC/3TC in HIV -1 infected subjects who are virologicall y 
suppressed (HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL) on a stable regimen 
containing ABC/3TC for  6 consecutive months prior to screening.
All subjects will be randomized, in a blinded fashion, in a 1:1 ratio to 
either switch from ABC/3TC to F/TAF + placebo -to-match ABC/3TC 
or maintain the ABC/3TC + placebo -to-match F/TAF while 
continuing the protocol allowed third agent (as prescribed b y the 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page7 11 March 2015Investigator) in their antiretroviral (ARV) regimen. Subjects who 
provide written consent and meet all eligibility  criteria will be 
randomized in a 1:1 ratio to one of the following two treatment arms:
Treatment Arm 1 : F/TAF + Placebo -to-match ABC/3TC; third 
antiretroviral agent remains the same (n =250)
Treatment Arm 2 : ABC/3TC + Placebo -to-match F/TAF; third  
antiretroviral agent rema ins the same (n =250)
Since different antiretroviral third agents require different doses of 
TAF, randomization will be stratified b y the third agents: boosted 
protease inhibitors vs. other agents (see below for protocol allowed 
third agents). 
Number of Subjects 
Planned:Approximately  500 subjects total withapproximately  250subjects 
each in Treatment Arm 1 and Treatment Arm 2.
Target Population: HIV-1 infectedadult subjects who are virologically  suppressed 
(HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mL ) on a stable regimen containing 
ABC/3TC for  6 consecutive months prior to screening.
Duration of 
Treatment:Subjects will be treated for [ADDRESS_893130] been 
unblinded. After unblinding, in countries where F/TAF FDC is not 
commerciall y available, subjects will be given the option to receive 
the open-label F/TAF FDC and attend study  visits every  12weeks 
until it becom es commercially available, or until [COMPANY_009] Sciences 
terminates the study  in that country .   
Diagnosis and Main 
Eligibility  Criteria:HIV-1 infectedadult subjects who meet the following criteria will be 
given the option to participate in the study :
Currently receiving an antiretroviral regimen containing 
ABC/3TC in combination with one third agent for 6consecutive 
months prior to screening
Plasma HIV -1RNA < 50 copi[INVESTIGATOR_014]/mL  for ≥ 6 months preceding the 
screening visit (measured at least twice using the s ame assay ) and 
not experienced two consecutive HIV -1 RNAmeasurements
above detectable levels after achieving a confirmed (two 
consecutive) HIV -[ADDRESS_893131] y ear. Plasma HIV -1 RNA 
should be < 
50 copi[INVESTIGATOR_014]/mL at the screening visit
Estimated glomerular filtration rate 50mL/min 
(Cockcroft -Gault formula)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page8 11 March 2015Study Procedures/
Frequency :After screening, eligible subjects will be randomized to Treatment 
Arm 1 or 2 and treated for 96 weeks. Followin g the Screening and 
Day 1 visits, subjects will return for study  visits at Weeks 4, 8, 12, 
and then every  12 weeks through Unblinding Visit .  
Laboratory  analyses (hematology , chemistry , and urinaly sis), HIV-1
RNA, CD4+ cell count, and complete or s ymptom directed ph ysical 
examinations will be performed at the Screening, Day  1, and all 
subsequent study  visits. 
For all subjects, dual energy  x-ray absorptiometry (DXA) scans will 
be performed prior to study  drug administration at Day  1 and every  
24 weeks unti l Week 96, at Unblinding Visit and at Early  Study Drug 
Discontinuation (ESDD), if > [ADDRESS_893132] scan. Scans will 
cover the spi[INVESTIGATOR_662137] y. 
Analyzed DXA scans will be provided to study  sites when available.
Blood and urine for selected evaluations of renaltubular function and 
boneturnoverwill be collected at Day  1, Weeks 4, 12, 24, 48, 72, 96 
and ESDD (if applicable). I n addition, blood will be collected and 
stored at Day  1, Weeks 4, 12, 24, 48, 72, and 96 and ESDD (if 
applicable) for possible evaluation of inflammation and immune 
activation, including cy statin-
C, IL-6, hs- CRP, d-dimer, sCD14, and 
sCD163. Platelet function evaluations will also be assessed, including 
soluble gl ycoprotein VI (sGPVI), P -selectin, and soluble CD40 
ligand.
A single PK blood sample will be collected an y time pre or post -dose 
at Weeks 8, 12, 24, and 36. At Weeks [ADDRESS_893133]- dose.
A whole blood sample will be collected at Week 4visit for 
assessment of archived provirus in peripheral blood mononuclear 
cells (PBMCs).
In a subset of patients, platelet function will be assessed at Day  1 
visit,Weeks4 and 12, and the Earl y Study Drug D iscontinuation 
Visit (if applicable). 
Subjects who complete the study  through the Unblinding Visit and do 
not wish to continue to participate will be required to return to the 
clinic 30days after the completion of the study  drug for a 30 -Day 
Follow-
up Visit.
Adverse events and concomitant medications will be assessed at each 
visit.
F/TAF
Protocol GS -US-311-[ADDRESS_893134], Dose, 
and Mode of 
Administration:F/TAF FDC tablet administered orall y once a day (QD). 
Recommended F/TAF dose by  [CONTACT_3252]-administered third agent:
Treatment Arm [ADDRESS_893135] Agents
F/TAF (200/10 mg)LPV/r,ATV+RTV, ATV+COBI (or ATV/ COBI 
FDC),  DRV+RTV, DRV+COBI (or DRV/COBI 
FDC)
F/TAF (200/25 mg) EFV, RPV, RAL, DTG, MVC, NVP
Reference Therapy, 
Dose, and Mode of 
Administration:ABC/3TC (600/300 mg) FDC tablet administered orally  once a day  
(QD)
Criteria for 
Evaluation:
Safety: Adverse events, clinical laboratory  tests (including selected 
evaluations of renaltubular function , boneturnover, and 
inflammation ), and DXA to evaluate the safet y and tolerability  of the 
two regimens
Efficacy: The primary  efficacy endpoint is the proportion of subjects with 
HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 48 as defined by  [CONTACT_4469] (FDA) snapshot algorithm.
Other secondary  endpoints include: 
The proportion of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at 
Weeks96 as defined b y the FDA snapshot algorithm
The percent change from baseline in hipand spi[INVESTIGATOR_110071]48and Week 96
Pharmacokinetics :The PK of indi vidual analy tes may be explored.
Statistical Methods: The primary  analysis will consist of a non- inferiority  evaluation of 
switching to F/TAF versus maintaining ABC/3TC, with respect to the 
proportion of subjects with HIV- 1 RNA less than 50 copi[INVESTIGATOR_014]/mL  at 
Week48 (as defined b y the FDA snapshot a lgorithm). I t will be 
concluded that F/TAF is non-inferior to the ABC/3TC if the lower 
bound of the two -sided 95% confidence interval of the difference 
between treatment arms (F/TAF –ABC/3TC) in the response rate i s 
greater than −
10% (i.e. a margin of 10% is applied to non- inferiority  
assessment). The 95% confidence interval will be constructed using 
the normal approximation method based on stratified 
Mantel-Haenszel proportions, where the stratification factor is the 
third agents (boosted protease inhibitors vs. other agents).
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page10 11 March 2015The secondary  analysis evaluating switching to F/TAF versus 
maintaining ABC/3TC, with respect to the percent change from 
baseline in hip and spi[INVESTIGATOR_662138] (ANOVA), including the third agent stratum as a fixed 
effect.
The adverse events and clinical laboratory data will be summarized 
using descriptive statistics.
Sample Size: A total of approximately  500HIV-1 infected subjects, randomized in 
a 1:1 ratio to two arms ( 250subjects per arm), achieves at least 90%
power to detect a non -inferiority  margin of 10% in Week 48 response 
rate (HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL  as defined b y the FDA snapshot 
algorithm ) difference between the two groups. For sample size and 
power computation, it is assumed that both treatment arms have a 
response rate of 0.87, that a non -inferiority margin is 0.10, and that 
the significance level of the test is at a one
-sided 0.025 level.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page11 11 March 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
3TC lamivudine 
ABC abacavir
AE adverse event
AIDS Acquired Immune Deficiency Syndrome
ALT alanine aminotransferase
ANC absolute neutrophil counts
ANOVA analysis of variance
ARV antiretroviral
AST aspartate aminotransferase
ATR Atripla®; EFV/FTC/TDF
ATV atazanavir 
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
AUClast area under the plasma concentration -time curve from time [ADDRESS_893136] 
measurable concentration
AUCtau area under the plasma concentration -time curve at the end of the dosing 
interval
AV atrioventricular
BMD bone mineral density
BUN blood urea nitrogen
CBC complete blood count
CK creatine kinase
CI confidence interval
CLcr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CNS central nervous system
COBI, /co cobicistat 
CPK creatine phosphokinase
CRF case report form(s)
CRO contract (or clinical) research organization 
CSR clinical study r eport
CTX type 1 collagen crosslinked C -telopeptide
CYP cytochrome P450
DDI drug-drug interaction
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page12 11 March 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS (CONTINUED)
DRV darunavir
DSPH Drug Safety and Public Health
DTG dolutegravir
DXA dual-energy X-ray absorptiometry
ECG electrocardiogram
EDC electronic data capture
eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
EFV efavirenz
EVG elvitegravir 
E/C/F/TDF elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 
200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single tablet regimen
E/C/F/TAF elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 
200 mg/tenofovir alafenamide (TAF) 10 mg single tablet regimen
ESDD early study drug discontinuation
FAS full analysis set
FDA ([LOCATION_002]) Food and Drug Administration
FDC fixed dose combination
FTC emtricitabine
F/TAF emtricitabine/tenofovir alafenamide
FTC/TDF emtricitabine/tenofovir disoproxil fumarate
GCP Good Clinical Practice (Guidelines)
GGT gamma glutamyl transferase
GSI [COMPANY_009] Sciences, Inc.
GS-7340  tenofovir alafenamide, TAF, L -Alanine, N -[(S)-[[(1R)-2-(6-amino-9H-purin-
9
-yl)-1-methylethoxy]methyl ]/ phenoxyphosphinyl] -, 1-methylethyl ester
HAART highly active antiretroviral therapy
HBsAg hepatitis B virus surface antigen serology
HBV hepatitis B virus
HCV hepatitis C virus
HCVAb hepatitis C virus serology
HDPE high-density polyethylene
HIV human immunodeficiency virus
HLGT high-level group term
HLT high-level term
HSP hysterosalpi[INVESTIGATOR_662139]’s brochure
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page13 11 March 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS (CONTINUED)
IEC Independent Ethics Committee
IND Investigational New Drug (Application)
INSTI integrase strand transfer inhibitor
IMP Investigational Medicinal Product
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
KS Kaposi’s sarcoma
LDH lactate dehydrogenase
LLN lower limit of the normal range
LLT low-level term
LPV lopi[INVESTIGATOR_662140]-nucleoside reverse transcriptase inhibitor
N[t]RTI nucleos(t)ide reverse transcriptase inhibitor
NOAEL no observed adverse effect level
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
NVP nevirapi[INVESTIGATOR_050]
P1NP procollagen Type 1 N -terminal propeptide
PBMCs peripheral blood mononuclear cells
PI [INVESTIGATOR_662141], /r ritonavir
SADR serious adverse drug reaction
SAE serious adverse event
SOC system organ class
SOP standard operating procedure
STB Stribild®, EVG/COBI/FTC/TDF (E/C/F/TDF) STR
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page14 11 March 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS (CONTINUED)
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide (GS -7340)
TAFfumarate tenofovir alafenamide fumarate (GS -7340-03)
TDF tenofovir disoproxil fumarate
TFV tenofovir
TFV-DP tenofovir diphosphate (TFVpp)
Tmax the time (observed time point) of Cmax
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
US [LOCATION_002]
WBC white blood cells
z terminal elimination rate constant, estimated by [CONTACT_662158], pl asma concentration of drug versus 
time curve
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page15 11 March [ZIP_CODE]. INTRODUCTION
1.1. Background
HIV-1 infection is a life -threatening and serious disease of major public health significance, with 
approximately  35million people infected worldwide { [ZIP_CODE]}. Standard of care for the treatment 
of HIV-1 infection uses combination antiretroviral therapy  (ART) to suppress viral replication to 
below detectable limits, increase CD4 cell counts, and stop disease progression. 
The success of pot ent and well- tolerated ART means that morbidity  and mortality  in the 
HIV-infected population is increasingly  driven by  [CONTACT_105]-AIDS–associated comorbidities. Clinical 
attention has become more focused on optimizing tolerability , long-term safety , and adherence
{[ZIP_CODE]}.There remains a significant medical need for safe and effective new therapi[INVESTIGATOR_662142], non -HIV–related comorbidities, virologic 
resistance, and regimen si mplification.
For ART- naive HIV -infected patients, treatment guidelines recommend that initial therapy  
consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI s) and either a nonnucleoside 
reverse transcriptase inhibitor (NNRTI), a boosted prot ease inhibitor (PI), or an integrase 
strand-transfer inhibitor (INSTI). Virologically  suppressed, HIV -infected patients can benefit by  
[CONTACT_662159] y or tolerability or to simplify the regimen 
{[ZIP_CODE]}, {[ZIP_CODE]}.
Tenofovir (TFV) is a nucleotide analog with limited oral bioavail ability that inhibits HI V-1 
reverse transcription. Tenofovir disoproxil fumarate (TDF) is an oral prodrug of TFV. While 
TDF is used broadly
 in the treatment of HIV -1 infection, nephrotoxicity  is an identified risk, and 
reductions in bone mineral density  (BMD) have been shown that are larger than those seen with 
other NRTIs { [ZIP_CODE]}.
TDF in combination with emtricitabine (FTC) forms a guideline -recommended N(t)RTI 
backbone for ART -naive HIV -infected patients that can be combined with different third agents. 
The combination of FTC and TDF is used within several once -daily fixed-dose combinations 
(FDCs) (Truvada®[FTC/TDF], Atripla®[efavirenz/FTC/TDF], Complera®or Eviplera®
[rilpi[INVESTIGATOR_12979]/FTC/TDF], and Stribild®[elvitegravir/cobicistat/FTC/TDF]). Availability  of a 
stand-alone NRTI backbone is important when there is a medical need to use a third agent that is 
not part of an FDC (eg, ritonavir- boosted PIs), and particularl y to provide a range of treatment 
options in patients with virologic resistance to their third agent but not to the backbone.
Tenofovir alafenamide (TAF) is an investigational oral prodrug of TFV. TAF is more stable in 
plasma than TDF. It provides higher i ntracellular levels of the active phosphory lated metabolite 
tenofovir diphosphate (TFV -DP), and approximately  90% lower circulating levels of TFV 
relative to TDF. The distinct metabolism of TAF offers the potential for an improved clinical 
profile compared with TDF.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page16 11 March 2015[COMPANY_009] Sciences ([COMPANY_009]) has coformulated TAF (as TAF fumarate) with FTC into an FDC 
tablet. 
1.2. Emtricitabine/Tenofovir Alafenamide (F/TAF)
F/TAF is a fixed- dose combination (FDC) tablet containing two medications: emtricitabine 
(FTC) and tenofovir alafenamide (TAF).  
The safety of F/TAF FDC is based on two y ear-long clinical studies (GS -US-292-0104 and 
GS-US-292-0111) in which 866 treatment- naïve subjects received E/C/F/TAF FDC . The 
following adverse drug reactions have been identified for F/TAF : 
Very common (more than or equal to 10%): headache, diarrhea, and nausea
Common ( ≥ 1% and < 10%): vomiting, abdominal pain, dy spepsia , flatulence, rash, and 
fatigue
Across all Phase 2 and Phase 3 studies in which 2,394 subjects received E/C/F/TAF FDC, ey e 
disorders were uncommon, balanced between treatment arms, and most were considered b y the 
investigator as unrelated to the study  drugs. None were definitive for posterior uveitis, and none 
resulted in permanent discontinuation of study  drugs. One subject in Study  GS
-US-292-0106 had 
an adverse reaction of intermediate uveitis (inflammation in the middle of the ey e) that was 
considered related to study  drug by [CONTACT_662160] e subject continued on 
study drug without interruption.
For further information on F/TAF, refer to the currentversion of the investigator’s brochure for 
F/TAF.
1.3. Tenofovir Alafenamide (TAF, GS 7340)
1.3.1. General Information
Tenofovir alafenamide (GS- 7340, TAF, or L-Alanine, N -[(S)-[[(1R)-
2-(6-amino-9H- purin -9-yl)-
1-methylethoxy]methyl]/phenoxy phosphiny l]-, 1-methylethyl ester) is a second generation oral 
prodrug of tenofovir (TFV), a nucleotide analog that inhibits HI V-1 reverse transcription. 
Tenofovir is metab olized intracellularl y to the active metabolite, tenofovir diphosphate 
(TFV-DP), a competitive inhibitor of HI V
-1 reverse transcriptase (RT) that terminates the 
elongation of the viral DNA chain. In the development of TAF, three forms of the drug substance
have been used in various studies: GS- 7340, synonym for GS-7340 as the free base; 
GS-7340-02, synonym for TAF monofumarate (1:1); and GS -7340-03 as the hemifumarate (2:1). 
GS 7340 03, also known as TAF fumarate, is considered comparable based on phy sical/
chemical 
properties to GS -7340-
02 that has been used in previous studies and a number of ongoing 
studies. GS-7340- 03 was also used in the Phase 2 study  GS US 292 -0102 and is being used in 
several ongoing Phase 3 studies (for example: GS
-US-292-0104 and GS -US-
292-0111). 
GS-7340-[ADDRESS_893137] as the free base, TAF (GS -7340), in blood and biological 
fluids.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page17 11 March [ZIP_CODE].3.2. Preclinical Pharmacology and Toxicology
[IP_ADDRESS]. Primary Pharmacody namics
TAF is metabolized to TFV, a nucleotide analog (i.e., a nucleoside monophosphate analog) 
which is not dependent on an intracellular nucleoside kinase activit y for the first step in the 
conversion to the active metabolite, TFV diphosphate (TFV- DP). The cellular enzy mes 
responsible for TFV metabolism to the active diphosphory lated form are adeny late kinase (AK ) 
{13}andnucleotide diphosphate kinase, which are highl y active and ubiquitous. AK exists as 
multiple isozy mes (AK1 to AK4), with the phosphory lation of TFV mediated most efficientl y by 
[CONTACT_184893]2.
The intracellular metabolism of TAF and TFV are consistent with the 600 fold enhancement in 
anti-HIV activity  in cell culture of TAF over TFV. Metabolism of TAF was also studied in 
different human blood l ymphocyte subpopulations, CD4+ and CD8+ T cells, NK cells, B cells 
andmacrophages/monocy tes. TAF is metabolized inside host cells to the active metabolite TFV 
DP. Concentration of the active metabolite TFV-DP was substantial in all cell populations.
[IP_ADDRESS]. Safety Pharmacology
TAF monofumarate (GS -7430-02) has been evaluated to det ermine potential effects on the 
central nervous s ystem (R990188), renal s ystem (R990186), cardiovascular (D2000006) and 
gastrointestinal s ystems (R990187). Single doses did not induce pharmacologic effects on the 
central nervous s ystem of the rat (1000 mg/ kg), the renal s ystem of the rat (1000 mg/kg), or the 
cardiovascular s ystem of the dog (100 mg/kg). TAF monofumarate (at 1000 mg/kg reduced 
distal transit and increased stomach weights starting 2 hours postdosing with reversibility  
beginning b y 6 hours aft er dosing. The NOEL for gastrointestinal motility  was 100 mg/kg. The 
IC50 for the inhibi tory effect of TAF fumarate (GS -7340-03) on hERG potassium current was 
estimated to be greater than 10 μM.
1.3.3. Nonclinical Pharmacokinetics
All nonclinical pharmacokinetic experiments in this section were performed using TAF 
monofumarate (GS -7340-02), and all stud y data described in this section reflect the dosage of the 
monofumarate. For reference, 100 mg of TAF monofumarate is equivalent to 80 mg of the 
GS-7340 free base ( TAF).
Plasma pharmacokinetics of the intact prodrug, TAF, following oral administration of 
GS-7340-02 in dogs and monkey s demonstrated rapid absorption with peak plasma 
concentrations between 0.25 and 0.5 hours. 
Peak TFV plasma concentrations occurred following TAF absorption, with TFV T maxvalues 
between 0.25 to 1.7 hours in rats, dogs, and monkeys. TFV plasma concentrations declined with 
a terminal half -life of 11.2 to 16.4 hours in rats (fasted), > 24 hours in dogs (fasted) and 8.1 to 
12.5 hours in rhesus monkey s. 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page18 11 March 2015The tissue distribution and recovery  of [14C] radiolabeled GS -7340-[ADDRESS_893138] in kidney, PBMCs, liver, large intestine, and bile. Significant concentrations of 
TFV related radioactive material were observed in ly mph nodes suggesting that TAF may  be 
selectivel y cleaved to te nofovir in the cells of the ly mphoreticular s ystem.
The primary  route of elimination of tenofovir is renal excretion of unchanged drug based on IV 
studies of tenofovir. Following oral administration of GS -7340-02, approximately  15% of a 
radiolabeled dose i s recovered in dog urine in 24 hrs. Tenofovir was the major species present in 
the urine (90%), with about 3.4% of TAF also present. Biliary  excretion of tenofovir in dogs and 
fecal elimination of tenofovir in rats and dogs are negligible.
Tenofovir was th e only species found in the intestinal contents and feces. In human sy stems, 
TAF is metabolized by  [CONTACT_506462], to a lesser extent, by  [CONTACT_097]3A4 catal yzed 
oxidation (AD -120-2004). As a result of the limited metabolism of TAF by [CONTACT_097]3A4 inhibition 
o
r induction of this enzyme should have little consequence on TAF exposure in vivo. TAF has 
limited potential to alter CYP enzy me activity  through inhibition and does not inhibit UGT1A1 
function. In addition, TAF is not an activator of either the ary l hydrocarbon receptor (AhR) or 
human pregnane -X-receptor (PXR). These features combined with the relatively  low plasma 
exposures of TAF in humans suggest that the potential of TAF to cause or be affected b y 
clinically relevant drug -drug interactions is very  low.
1.3.4. Nonclinical Toxicology
TAF monofumarate (GS -
7340-02) was evaluated in mice, rats, dogs, and monkey s for treatment 
periods up to 9 months and was negative in genetic toxicology  studies.
In chronic studies in rats, bone (atroph y of metaphyseal cancellous bo ne) and kidney s 
(karyomegaly) were the primary  target organs after 26 weeks of treatment. GS -7340-02 also 
appeared to increase biochemical markers of bone turnover and decrease serum 1,25 dihy droxy  
and 25 hy droxyvitamin D3 at doses of 25 mg/kg/day  and above.  In chronic studies in dogs after 
9 months of treatment with GS -7340-02, the primary  target organs were kidney  and bone. This 
chronic toxicity  study of TAF in beagle dogs given 2mg/kg/day , 6 mg/kg/day  or 12-
18 
mg/kg/day  for 9 months found non- specific mononuclear cell infiltrates seen on histopathology  
in the lungs, spleen and posterior uvea (ey e) of animals in the 12 18 mg/kg group. This group of 
animals experienced generalized debility  at the 18 mg/kg/day  dose, so the dose was decreased 
after Week 6. 
The histopathologic changes were felt to be due to the overall condition of the 
animals and not specific TAF -related toxicity . There were no findings in the ey es of dogs treated 
with lower doses (2 mg/kg and 6 mg/kg), and it was concluded that the NOAEL  inbeagle dogs 
was 2 mg/kg/day .
TAF monofumarate had no discernible electrocardiograph effect at the low dose of 2 mg/kg/day 
and slightly  prolong PR intervals at 6 and 12- 18 mg/kg/day . Additionall y, at Week 39, TAF 
monofumarate appeared to reversibl y reduce heart rate with an associated mild QT prolongation. 
At Week 39, decreases in serum T3 were noted for animals receiving 18/12 mg/kg/day  but was 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page19 11 March 2015reversible at the 3 -month recovery  period. Minor hematological and biochemistry  parameters 
changes were observed but remained within normal historical ranges with the following 
exceptions: AST (~ 100% increase) and total bilirubin (~40% increase). There were no clear 
treatment -related effects observed in monkey s following 28 days of treatment including no 
changes in mitochondrial function.
The data from the 6 -month rat study  determined a NOAEL of 25 mg/kg/day (tenofovir 
AUC=3758ng·h/mL); the 9 -month dog stud y defined a NOAEL of 2 mg/kg/day (tenofovir 
AUC=1180ng·h/mL), and the 28 -day nonhuman primate study  defined a NOAEL of 
30mg/kg/day  (tenofovir AUC = 5870 ng·h/mL). In conjunction with the nonclinical data with 
TDF and the clinical experience with TDF and TAF, these toxicology  studies support studies in 
humans of doses up to 150 mg/day  ([ADDRESS_893139] anticipated human dose) for 
chronic treatment.
At the time of the rodent toxicity studies, the bioassay  could not detect plasma TAF, possibl y due 
to instability  in the matrix.
Because of the lack of exposure to the prodrug in mice and rats and achie vable tenofovir 
exposures less than previously  tested in chronic and carcinogenicity  studies with TDF, 
carcinogenicity  studies in mice and rats with TAF are not required per agreement with the FDA. 
Also, TAF does not need to be evaluated in perinatal- postnatal reproductive toxicology  studies 
per agreement with the FDA. Reproductive tissues were examined in repeat -dose toxicology  
studies in the rat, dog, and monkey . There were no clearl y treatment -related histologic alterations 
or changes in organ weights i n the rat and the dog following chronic dail y dosing, or in the 
monkey. 
The TAF fumarate (GS -7340-03) oral rat fertility  study is ongoing (Report No. TX -120-2012, 
report in progress). 
1.3.5. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) or 
Fixed Dose Combination emtricitabine/tenofovir alafenamide (F/TAF)
A proof-of-
concept study, GS- US-120-0104, evaluated monotherap y, with three lower doses of 
TAF or TDF 300 mg, or placebo, administered in a fasted state for 10 days. Potent antiviral 
activity was achieved in treatment- naïve HIV -1 infected patients, with mean (± SD) change from 
baseline in HIV -1 RNA of 
-0.98 ± 0.46, - 1.50 ± 0.41, -1.74 ± 0.19, and  0.81± 0.58 log10 
copi[INVESTIGATOR_014]/ml at 8 mg, 25 mg, 40 mg dose of TAF, and TDF 300 mg, respectively . Mean viral load 
declines for both the 25 mg and 40 mg doses were statistically  greater than the 8 mg dose. TAF 
exposure (AUC) was best associated with antiviral activity  despi[INVESTIGATOR_184797]- life 
(~30min). TFV AUC were 97%, 87%, and 80% lower at 8 mg, 25 mg, and 40 mg TAF 
compared to TDF administration. When compared to 40 mg and historical 120 mg data, 25 mg 
TAF provides near maximal activity  (predicted to be ~ 1.7 to1.8 log10 c/mL). From this PK -PD 
analysis, a target dose of 20 25 mg TAF monothe rapy is expected to provide near maximal 
activity and ~ 90% reduction in circulating TFV.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page20 11 March 2015The drug interaction potential of F/TAF with other antiretroviral agents was evaluated in 
GS-US-311-0101 (EFV, DRV/co, COBI), GS- US-120-0117 (RPV), and GS -US-120-0118 
(ATV/r, LPV/r, DRV/r, and DTG). The effect of third agents on TAF exposures are summarized 
in Table1-1.
Table1-1. GS-US-311-0101, GS-US-120-0117, and GS- US-120-0118: Changes in 
TAF exposures when Coadministered with Third Agents
Coadministered Third Agent TAF AUC (% change) (90% CI)
EFV ↓14 (↓28 to ↑2)
DRV/co ↓2 (↓20 to ↑19)
COBI ↑165 (↑129 to ↑207)
RPV ↓4 (↓17 to ↑10)
ATV/r ↑91 (↑55 to ↑135)
LPV/r ↑47 (↑17 to ↑85)
DRV/r ↑6 (↓16 to ↑35)
DTG ↑19 (↓4 to ↑48)
In StudyGS-US-311-1386, the effect of food (high- calorie, high- fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GL SM ratio of the AUC lastof TAF when 
administered with a high -fat meal was 177% (90% CI: 166% to 188%), and the TAF C max
GLSM ratio was 84.5% (90% CI:74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma C maxwhen administered with food was 
accompanied b y a delay in T max(increase from 1.00 hour under fasted conditions to 2.00 hours 
under fed conditions). The exposures of TAF observed under fed or fasted conditions in this 
study are within the range of exposures observed in the E/C/F/TAF clini cal development 
program and are commensurate with safe and effective plasma levels of TAF (see investigator 
brochure for further details). Therefore, the changes in TAF exposures when F/TAF is 
administered with food should not result in differences in effi cacy and thus are not clinicall y 
relevant. TAF can be administered without regard for food and these findings can be 
extrapolated to F/TAF (as FTC can be taken without regard to food). 
Dose selection considerations for F/TAF that rel y on these anal yses are outlined in Table1-2. 
Further details for the above clinical studies and other clinical studies of TAF or F/TAF 
(e.g.TAF in subjects with renal impairment or hepatic impairment) are provided in the F/TAF 
investigator brochure. 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page21 11 March [ZIP_CODE].3.6. Clinical Trials of Elvi tegravir/Cobicistat/Emtricitabine/Tenofovir 
Alafenamide (E/C/F/TAF)
The individual components of F/TAF (ie, FTC and TAF) have been combined with the integrase 
inhibitor EVG and its pharmacoenhancer cobicistat (COBI, C) in the FDC product E/C/F/TAF, 
which has been designed to be a complete treatment regimen for HIV-1infection. The interim 
data of the 2 clinical studies in ART-naïve patients (GS- US-292-0104 and GS -US-292-0111) and 
1 in virologicall y suppressed patients (GS -US-292-0111) are summarized below. 
GS-US-292-0104 
This is a randomized, double -blind, multicenter, active -controlled stud y to evaluate the efficacy 
and safety of E/C/F/TAF FDC vs STB in HIV -infected, ART- naive adult subjects.
Eligible subjects were ART
-naive (excluding pre exposure prophy laxis [PREP] or post exposure 
prophylaxis [PEP], as admissible, up to 6 months prior to screening), HIV -infected adults with 
plasma HI V-1RNA ≥ 1,000 copi[INVESTIGATOR_014]/mL , a screening genot ype showing sensitivity  to EVG, FTC, 
and TDF, and an eGFR calculated using the Cockcroft Gault method ( eGFRCG) ≥ 50 mL/min at 
screening.
Subjects were randomized in a 1:1 ratio to one of the following 2 treatment groups:
Treatment Group 1: E/C/F/TAF FDC once daily + placebo -to-match STB once daily
Treatment Group 2: STB once daily + placebo -to-match E/C/F/TAF FDC once daily
This summary  describes the results of the study  through a data cutoff performed when all 
randomized subjects had completed the Week 48 visit, or had discontinued study  treatment 
before their Week 48 visit:
The Safet y Analysis Set and FAS included 867 (99.4%) subjects (E/C/F/TAF: 435 [99.3%] 
subjects, STB: 432 [99.5%] subjects).
For the primary  efficacy endpoint anal ysis (percentage of subjects with HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL at Week 48 using the FDA snapshot algorithm) using the FAS, virologic 
success rates were as follows: E/C/F/TAF 93.1%, STB 92.4%; difference in percentages 
(95.002% CI): 1.0% (2.6% to 4.5%). Because the lower bound of the 2 -sided 95.002% CI of 
the difference in the response rate (E /C/F/TAF – STB) was greater than the prespecified 12% 
noninferiority  margin, E/C/F/TAF was determined to be noninferior to STB. Noninferiorit y 
was confirmed using the Week 48 PP Analy sis Set.
Overall, the steady state plasma exposure of TAF and TFV, and intracellular exposure of 
TFV-DP, were in the range of historical data and concurrent study  data from the ongoing 
Phase 3 program. Compared with STB, administration of E/C/F/TAF led to an approximately  
90% reduction in mean systemic TFV AUC tauand a higher m ean PBMC TFV -DP AUC tau.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page22 11 March 2015The 48-week AE profile of E/C/F/TAF was generally  similar to that of STB with 
396 (91.0%) vs 392 (90.7%) subjects reporting any AE, and 36 (8.3%) vs 26 (6.0%) subjects 
reporting an y Grade [ADDRESS_893140] commonly  reported AEs ( ≥10% of subjects in 
either treatment group) were diarrhea, nausea, upper respi[INVESTIGATOR_2826], and 
headache. There were no clinically relevant differences in AE incidence between treatment 
groups.
As noninferiorit y of E/C/F/TAF to STB was establishe d, multiplicity  adjustments were 
performed for the 4 key  safety endpoints at Week 48 in sequential order using a fallback 
procedure with pre specified 2 sided alpha levels. Based on the adjusted alpha levels, there 
were statisticall y significant difference s favoring E/C/F/TAF over STB at Week 48 for all 
4safety endpoints: mean percentage changes from baseline in hip BMD (p < 0.001) and 
spi[INVESTIGATOR_9210] (p < 0.001), mean change from baseline in serum creatinine (p < 0.001), and 
incidence of treatment -emergent prot einuria (p = 0.034). Other findings of note regarding 
bone and renal safety included the following:
— The percentage of subjects with > 3% decrease from baseline to Week 48 in hip or spi[INVESTIGATOR_662143] E/C/F/TAF group than in the STB group (19.0% vs 54.7% for hip 
and 25.1% vs 45.4% for spi[INVESTIGATOR_050]), with statistically  significant differences between groups 
in the categorical distribution of percentage change from baseline to Week 48 in hip or 
spi[INVESTIGATOR_9210] (p <0.001).
—Decreases from baseline in median eGFR CGwere smaller in the E/C/F/TAF group than in 
the STB group (p <0.001), and changes from baseline to Week 48 in eGFR CKD-EPI,creatinine 
were consistent with those observed in eGFR CG.
—There were no AEs of proximal renal tubulopathy  (including Fanconi S yndrome) or 
laboratory  findings consistent with subclinical renal tubulopathy  in either treatment 
group.
There were no relevant differences in reported ey e findings for the study . No eye disorder 
AEs resulted in discontinuation of study  drug. There were no AEs of posterior uveitis during 
the study.
Although laboratory  abnormalities were common in both treatment groups, the incidence of 
Grade 3 or 4 abnormalities was balanced between treatment groups. Increases from baseline 
to Week 48 in total cholesterol, LDL, HD L, total cholesterol to HDL ratio, trigl ycerides, and 
serum glucose were larger in the E/C/F/TAF group than in the STB group (p ≤ 0.032), most 
likely representing a smaller protective TFV effect with E/C/F/TAF.
GS-US-292-0111
This is a randomized, double -blind, multicenter, active -controlled stud y to evaluate the efficacy 
and safety of E/C/F/TAF FDC vs STB in HIV -
infected, ART- naive adult subjects. This study  has 
the same study  objectives and an identical study  design to those of Study  GS
-US-292-0104, with 
the following exception:
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page23 11 March 2015While both studies have sites in North America and Europe, Study  GS-US-292-0104 
includes additional sites in Asia Pacific while Study  GS-US-292
-0111 includes additional 
sites in Latin America.
This summary  describes the results of the study through a data cutoff performed when all 
randomized subjects had completed the Week 48 visit, or had discontinued study  treatment 
before their Week 48 visit:
The Safet y Analysis Set and FAS included 866 (99.3%) subjects (E/C/F/TAF: 43 1[99.1%] 
subjects, STB: 43 5[99.5%] subjects).
For the primary  efficacy endpoint anal ysis (percentage of subjects with HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL at Week 48 using the FDA snapshot algorithm) using the FAS, virologic 
success rates were as follows: E/C/F/TAF 91.6%, STB 8 8.5%; difference in percentages 
(95.002% CI): 3.1% (1.0% to 7.1%). Because the lower bound of the 2 -sided 95.002% CI of 
the difference in the response rate (E/C/F/TAF –STB) was greater than the prespecified 12% 
noninferiority  margin, E/C/F/TAF was determi ned to be noninferior to STB. Noninferiorit y 
was confirmed using the Week 48 PP Analy sis Set.
Overall, the 48 -week safety  profile of E/C/F/TAF was generall y similar to that of 
GS-US-292-
0104.
GS-US-292-0109 
Study GS
-US-292-0109 is a randomized, open
-label, multicenter, active -controlled study  to 
evaluate the efficacy , safety, and tolerability  of switching to E/C/F/TAF from regimens 
containing FTC/TDF in virologicall y suppressed HIV -infected adult subjects. All subjects were 
drawn from a predefined set of G ilead clinical studies and were virologically  suppressed for at 
least 48 weeks with one of the following FTC/TDF- based regimens:
STB (Stribild®; EVG/COBI/FTC/TDF)
ATR (Atripla®; efavirenz (EFV)/FTC/TDF )
COBI booste d atazanavir (ATV/co)+FTC/TDF ( Truvada®; TVD)
ritonavir boosted atazanavir (ATV/r)+TVD
Subjects enrolled in this study  were HIV -infected adults receiving ART regimens for at 
least6consecutive months. All subjects were required to have plasma HIV -
1RNA levels at 
undetectable levels for at least 6consecutive months prior to the screening visit; HI V-1 RNA 
<50copi[INVESTIGATOR_014]/mL at the screening visit; and an eGFR CG50mL/min at screening. Subjects must 
have completed the Week 144 visit in Studies GS-US-236-0102 (US onl y study), 
GS-US-236-0103, or GS -US-216-0114; must have completed the Week 96 visit in 
StudyGS-US-264-0110 (subjects taking the EFV -based regimen onl y); or must have completed 
the primary  endpoint assessment visit in Studies GS -US-236-0104 or GS -US-216-0105.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page24 11 March 2015Subjects were randomized in a 2:1 ratio to one of the following 2 treatment groups:
Treatment Group 1: Switch to E/C/F/TAF FDC once daily
Treatment Group 2: Stay on preexisting FTC/TDF+3rd Agent regimen (STB, ATR, 
ATV/co+TVD, or ATV/r+TVD)
Randomization was stratified by  [CONTACT_598579] (ie, STB, ATR, ATV/boosted+TVD) at 
screening.
This data cutoff was performed when all subjects randomized by  31 October 2013 had been 
followed through the lower limit of Week 48 analy sis window (Week 42, or calendar date 
28August 2014) or had disc ontinued study  treatment before this time.
The Safet y Analysis Set included 1436 (99.5%) subjects (E/C/F/TAF: 959 [99.6%] subjects, 
FTC/TDF+3rd Agent: 477 [99.4%] subjects), and the Week 48 FAS included 1196 (82.9%) 
subjects (E/C/F/TAF: 799 [83.0%] subject s, FTC/TDF+3rd Agent: 397 [82.7%] subjects).
For the primary  efficacy endpoint anal ysis (percentage of subjects with HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL at Week 48 using the FDA snapshot algorithm) using the FAS, virologic 
success rates were as follows: E/C/F/TAF 95. 6%, FTC/TDF+3rd Agent 92.9%; difference in 
percentages (95% CI): 2.7% (- 0.3% to 5.6%). Because the lower bound of the 2 -sided 95% 
CI of the difference in the response rate (E/C/F/TAF – FTC/TDF+3rd Agent) was greater 
than the prespecified  12% noninferiorit y margin, E/C/F/TAF was determined to be 
noninferior to FTC/TDF+3rd Agent.
The incidence and severity  of all AEs, and the incidence of SAEs, AEs leading to premature 
study drug discontinuation, and deaths was similar between treatment groups. The incidence
of any study-drug related AE was higher in the E/C/F/TAF group (185 [19.3%] subjects) 
than in the FTC/TDF+3rd Agent group (61 [12.8%] subjects); however, the incidence of 
Grade 2, 3, or 4 study  drug-related AEs was similar between treatment groups (E/C/F/ TAF: 
46 [4.8%] subjects, FTC/TDF+3rd Agent: 20 [4.2%] subjects).
In this stud y, 4 key secondary  safety endpoints were defined and tested in sequential order 
using a fallback procedure at Week 48. Overall, there were statisticall y significant 
differences fa voring E/C/F/TAF over FTC/TDF+3rd Agent at Week 48 for all 4 key  
secondary  safety endpoints: mean percentage changes from baseline in hip BMD (p < 0.001) 
and spi[INVESTIGATOR_9210] (p < 0.001), mean change from baseline in serum creatinine (p < 0.001), and 
change from baseline in EFV -related symptom assessment composite score (p < 0.001). 
Other findings of note regarding bone and renal safet y included the following:
— The percentage of subjects with > 3% increase from baseline to Week 48 in hip or spi[INVESTIGATOR_662144] E/C/F/TAF group than in the FTC/TDF+3rd Agent group 
(25.2% vs 8.6% for hip and 33.6% vs13.8% for spi[INVESTIGATOR_050]), with statistically  significant 
differences between treatment groups in the categorical distribution of percentage change 
from baseline to Week 48 in hip or spi[INVESTIGATOR_9210] (p <0.001).
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page25 11 March 2015—Median (Q1, Q3) changes from baseline to Week 48 in eGFR CGin the E/C/F/TAF and 
FTC/TDF+3rd Agent groups were 1.8 (-6.6, 9.7) and -3.7 (-11.1, 3.6) mL/min, 
respectivel y (p < 0.001), and differences between treatment groups in change from 
baseline to Week 48 in eGFR CKD-EPI,creatinine were consistent with those observed in 
eGFRCG(p < 0.001). The difference between treatment groups in the distribution of 
proteinuria b y urinalysis (dipstick) adjusted for baseline status was statistically  significant 
at Week 48 (p =0.004).
— One subject in the FTC/TDF+3rd Agent group had a nonserious AE of acquired Fanconi 
syndrome; the event was considered related to the study  drug by [CONTACT_662161]. Otherwise, there were no AEs of proximal renal 
tubulopathy  (including Fanconi Sy ndrome) or laboratory  findings consistent with 
subclinical renal tubulopathy  in either treatment group.
There were no relevant differences in ey e findings for the study . Noeye disorder AEs 
resulted in discontinuation of study  drug. There were no AEs of posterior uveitis during the 
study. Among subjects who participated in the ophthalmologic substudy  (E/C/F/TAF: 
32subjects; FTC/TDF+3rd Agent: 15 subjects), only  [ADDRESS_893141] (E /C/F/TAF) with available 
postbaseline data had a treatment -emergent abnormality , specifically , the detection of a 
retinal hemorrhage in the left ey e. All other subjects had no new abnormalities relative to 
their baseline fundoscopic examination.
The incide nce of laboratory  abnormalities of any  grade was balanced between treatment 
groups for most chemistry , hematology , and urinaly sis parameters. Increases from baseline to 
Week 48 in total cholesterol, L DL, HDL, total cholesterol to HDL ratio, and trigl ycerides 
were larger in the E/C/F/TAF group than in the FTC/TDF+3rd Agent group (p ≤ 0.025), most 
likely representing a decrease in the protective TFV effect.
Further details for the above clinical studies and other clinical studies of E/C/F/TAF 
(e.g.E/C/F/TAF in HIV -infected subjects with renal impairment) are provided in the F/TAF 
investigator brochure.
1.3.7. Clinical Trials of Darunavir/Cobicistat/Emtricitabine/ TAF(D/C/F/TAF)
The individual components of F/TAF (ie, FTC and TAF) have been combined with COBI 
boosted DRV in the FDC product D/C/F/TAF for treatment of HIV-1infection.
Bioavailability  studies demonstrated that when administered as the D/C/F/TAF FDC (TAF 
10 mg), TAF exposures were comparable (and corresponding TFV exposures ~ 3 fold higher) to 
TAF 10-mg exposures, which is consistent with a mixed inhibitory /inductive effect of DRV and 
COBI on TAF absorption. TAF at 10- mg exposures was deemed appropriate for further 
evaluation due to the high antiviral activity of TAF at the 8- mg dose, similar to that of 
TDF-300mg as monotherapy  and given the potency  of this regimen.
A randomized, active -controlled Phase 2 Study  GS-US-299-0102 compared D/C/F/TAF versus 
DRV+COBI+FTC/TDF in ART -naive, HIV -infected subjects. 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page26 11 March 2015Results from the final analy sis demonstrated the following:
The proportion of subjects with plasma HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL using the Food and 
Drug Administration (FDA) snapshot algorithm was similar between treatment groups at 
Week24 (primary  efficacy endpoint) (74.8% in the D/C/F/TAF group and 74.0% in the 
DRV+COBI+TVD group), but numericall y lower in the D/C/F/TAF group at Week 48 
(76.7% in the D/C/F/TAF group and 84.0% in the DRV+COBI+TVD group).
At Week 48, the difference in rates of virologic success between treatment groups was 
primarily due to a di fference in the numbers of subjects who discontinued study  drug due to 
other reasons and had the last available HIV -1 RNA ≥ 50copi[INVESTIGATOR_014]/mL  (D/C/F/TAF: 8.7%; 
DRV+COBI+TVD: 4.0%) or < 50copi[INVESTIGATOR_014]/mL  (D/C/F/TAF: 6.8%; DRV+COBI+TVD: 
2.0%). 
Importantly , D/C/F/TAF demonstrated a potential benefit over DRV+COBI+FTC/TDF in 
terms of renal and bone safet y: smaller median decreases in eGFR CG(mL/min) (at Week 48, 
D/C/F/TAF -2.9 vs DRV+COBI+FTC/TDF - 10.6 [p=0.017]) and smaller mean percentage 
decreases in BMD (at Week 48, spi[INVESTIGATOR_050] D/C/F/TAF - 1.57% vs DRV+COBI+FTC/TDF - 3.62% 
[p=0.003], hip - 0.84% vs -3.82% [p <0.001]). These mean percentage changes from 
baseline to Week 48 in spi[INVESTIGATOR_662145] D/C/F/TAF are both lower than all 
published studies of Week 48 BMD data in ART-
naive subjects receiving an 
NRTI-containing ART regimen {[ZIP_CODE]}, {[ZIP_CODE]}, {[ZIP_CODE]}, {[ZIP_CODE]}. 
Treatment with D/C/F/TAF or DRV+COBI+TVD was generall y well tolerated during this 
study. No unexpected AEs were associated with the use of D/C/F/TAF through [ADDRESS_893142] treatmen t-emergent AEs were assessed as Grade 1 or Grade 2 in severit y. 
The incidence of Grade 3 AEs was comparable between the 2 groups (D/C/F/TAF 6.8%, 
DRV+COBI+TVD 8.0%). No Grade 4 AEs were reported during the stud y. Similar 
percentages of subjects in each tre atment group had SAEs (D/C/F/TAF 4.9% vs. 
DRV+COBI+TVD 4.0%), most of which were unrelated to study  drug.
1.4. Emtricitabine (FTC, Emtriva®)
Further information regarding Emtrivais available in the current investigator’s brochure and 
local label; an overview is provided below.
1.4.1. General Information
Emtricitabine (5 -fluoro-
1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan -5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HI V. In HIV infected adults, 
FTC is admi nistered as a 200 mg QD dose concurrently with other ARVdrugs. The 200 mg FTC 
capsule formulation was approved b y the US Food and Drug Administration (FDA) for 
marketing on 2 July  2003 and is available under the name [CONTACT_10881]®. In the European Union 
(EU), marketing authorization was granted for both the 200 mg Emtriva®capsule formulation 
and a 10 mg/mL  Emtriva®oral Solution formulation on 24 October 2003, with indications for the 
treatment of HIV infection concurrently  with other antiretroviral drugs in bo th adult and 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page27 11 March 2015pediatric patients. In pediatric patients, the recommended dose of Emtriva®is 6 mg/kg QD, up to 
a maximum of 200 mg QD when administered using the capsule formulation (for children 
weighing > 33 kg) or up to a maximum of 240 mg when administe red using the oral solution 
formulation.
1.5. Information about Fixed Dose Combination of Abacavir/Lamivudine 
(ABC/3TC, Epzicom, Kivexa)
Epzicomor Kivexais the brand name [CONTACT_662175] 
300 mg/lamivudine 600 mg (ABC/3TC). Epzicomor Kivexais recommended for use once 
daily in adults. 
Please refer to the latest version of the SmPC and/or Prescribing Information forEpzicomor 
Kivexafor additional information.
1.6. Rationale for This Study
[COMPANY_009] is developi[INVESTIGATOR_662146] -dose combination (FDC) product emtricitabine/tenofovir
alafenamide (F/TAF) for the treatment of HIV -1 infection in combination with other 
antiretroviral agents. TAF, one component of F/TAF is an improved prodrug for tenofovir, and 
f
or clinicians, F/TAF can provide flexibility  in constructing an effective antiretroviral regimen 
for patients.
The Phase 1 stud y (GS-US-120-0104) demonstrated that TAF has an improved pharmacokinetic
profile relative to TDF (longer plasma half -life, lower plasma TFV exposure, and high er
intracellular TFV -DP exposure) with greater antiviral activity  at 25 mg dose.
As a nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI s) backbone, F/TAF is being 
evaluated as part of E/C/F/TAF FDC (150/150/200/10 mg) in several Phase [ADDRESS_893143] patient populations. The interim data from these studies demonstrated potent efficacy  of 
E/C/F/TAF with improved renal and bone safety  profile relative to STBin ART-naive patients 
(GS-US-292-0104 and GS -US-292-0111) and to TDF -containing regimens (including 
E/C/F/TDF) in virologically  suppressed patients (GS -US-292-0109). In addition, the efficacy  and 
safety of F/TAF FDC (200/10 and 200/25 mg) is being evaluated in Stud y GS-US-
311-1089, an 
ongoing, Phase 3, randomized, double -blind study in HIV -infected subjects who are virologically  
suppressed on regimens containing FTC/TDF. 
As ABC/3TC is another N[t]RTI s backbone for the treatment of HIV- [ADDRESS_893144] a randomized control led study in 
patients who are virologically  suppressed on a ABC/3TC containing regimen that compares 
efficacy and safet y between patients who switch to F/TAF vs. those who maintain ABC/3TC 
while continuing the same third agent.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page28 11 March [ZIP_CODE].7. Rationale for Dose Selection
The 200 mg dose of FTC represents the marketed dose for this agent that is currentl y available as 
single agent capsules (E mtriva) and as a component of a number of fixed -dose combination 
tablets, including: T ruvada, Atripla, Complera/Eviplera, and Stribild.
The recommended dose of F/TAF (200/10 mg or 200/25 mg) per third ARV agent is based on 
ensuring that patients have a TAF s ystemic exposure that is comparable to the TAF 25 mg
exposure, the common reference exposure for which an extensive E/C/F/TAF safety and efficacy 
database exists.
The different TAF dose (10 or 25 mg) is generally based on whether or not the coadministered 
third agent has an y clinically relevant effect on TAF (eg, via inhibition of intestinal Pgp, termed 
as “boosting” for simplic ity).
Specificall y, F/TAF (200/10 mg) will be used with third agents that substantially increase TAF 
exposure (ATV/r, LPV/r), and F/TAF (200/25 mg) will be used with third agents that do not 
have clinicall y relevant effect on TAF exposure (EFV, RPV, DTG). Although DRV/r did not 
demonstrate an y clinically relevant “boosting” effect on TAF, clinical data from a Phase 2, 
randomized, double -blind, active- controlled study evaluating efficacy  and safet y of a regimen 
containing D/C/F/TAF compared with DRV+COBI+FTC /TDF in HIV-1 infected, ART- naïve 
subjects provides support for using F/TAF 200/10 mg with DRV/r. In that study , D/C/F/TAF was 
noninferior to DRV+COBI+TVD when administered for 24 weeks using the FDA snapshot
algorithm with HIV -1 RNA cutoff at 50 copi[INVESTIGATOR_014]/mL , in accordance with the primary  objective of 
this study . 
Based on these considerations, t he proposed dose of F/TAF FDC tablets per third ARV agent is 
listed in Table1-2
, whichpresents the TAF -equivalent dose achieved based on sy stemic TAF 
exposure resulting from administration of the recommended F/TAF dose with each 
coadministered third ARV agent.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page29 11 March 2015Table1-2. Dose Recommendations for F/TAF with Potential Concomitant 
Antiretroviral Drugs
ARV DrugRecommended F/TAF Dose
(mg)TAF-Equivalent Dosea
(mg)
EFV 12b
RPV 24
DTGc
200/2517b/30
RAL —d
MVC —d
NVP —d
ATV+COBI —e
ATV+RTV 19
DRV+COBI 200/10 11
DRV+RTV 11
LPV/r 15
TAF-Equivalent Dose calculated based on percentage change in TAF AUC with/without coadministered drug.
aExpected exposure in fed state unless otherwise noted.
bExpected exposure in fasted state.
c Because DTG may be administered without regard to food, expected exposures are provided for both the fed and fasted 
states.
d No DDI study performed. Dosing recommendation based on the nonclinical profiles of TAF and the specified ARV.
e No DDI study performed. Dosing recommendation extrapolated based on nonclinical information and the DDI study 
between TAF and ATV+RTV.
While no clinical drug -drug interaction studies of TAF were conducted with raltegravir (RAL), 
MVC and NVP, no clinically  relevant drug -drug interaction is expected based upon nonclinical 
and clinical information.
Taken together, F/TAF (200/10 or 200/25 mg) in combination with the appropriate third agent 
can achieve plasma TAF exposure that is associated with potent antiviral activity  and with lower 
plasma TFV exposure than that seen with TDF [ADDRESS_893145] agents and the correspondin g F/TAF dose are presented in 
Table3-1. 
Lastly, the food effect on TAF was evaluated when administered as part of E/C/F/TAF FDC 
(GS-US-292-0110) and as F/TAF FDC (GS -US-311-1386). Under fed conditions (high fat 
meal), TAF exposures increased b y 17% with E/C/F/TAF FDC and 77% with F/TAF FDC 
However, these TAF exposures observed under fed or fasted conditions in this study  are within 
the range of exposures observed in the E/C/F/TAF FDC clinical development program and are 
commensurate with safe and effectiv e TAF exposure. Therefore, these data support the 
administration of F/TAF without regard to food.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page30 11 March [ZIP_CODE].8. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page31 11 March [ZIP_CODE]. OBJECTIVES
The primary  objective of this study  is:
To evaluate the efficacy  of switching ABC/3TC to F/TAF versus maintaining ABC/3TC in 
HIV-1 infected subjects who are virologically  suppressed on regimens containing ABC/3TC 
as determined b y the proportion of subjects with HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 48 
The secondary  objectives of this study  are:
To evaluate the efficacy , safety and tolerability of two regimens through Week 48 and 
Week96
To evaluate the bone safety  of two regimens as determined by  [CONTACT_662162][INVESTIGATOR_662147] y (BMD) throughWeek 48 and Week 96
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page32 11 March [ZIP_CODE]. STUDY DESIGN
3.1. Endpoints
The primary  endpoint of this study  is:
The proportion of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 48 as defined by  [CONTACT_662163]:
The proportion of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Weeks 96 as defined by  [CONTACT_662164]
The percent change from baseline in hipand spi[INVESTIGATOR_110075] 48 and Week 96
3.2. Study Design
This protocol describes a r andomized, double -blind, multicenter, active -controlled study  to 
evaluate the safet y and efficacy of switching ABC/3T C to F/TAF fixed- dose combination (FDC) 
tablet versus continuing ABC/3TC in HIV -1 infected subjects who are virologicall y suppressed 
(HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mL ) on a stable regimen containing ABC/3TC for 6 consecutive 
months prior to screening.
All subjec ts will be randomized, in a blinded fashion, in a 1:1 ratio to either switch from 
ABC/3TC to F/TAF + placebo- to-match ABC/3TC or maintain the ABC/3TC + placebo -to-
match F/TAF while continuing the protocol allowed third agent (as prescribed by  [CONTACT_3786]) in their antiretroviral (ARV) regimen.
3.3. Study Treatments
Subjects who provide written consent and meet all eligibility  criteria will be randomized in a 1:1 
ratio to one of the following two treatment arms:
Treatment Arm 1 : F/TAF + Placebo -to-match ABC/ 3TC; third antiretroviral agent remains the 
same (n=250)
Treatment Arm 2 : ABC/3TC + Placebo -to-match F/TAF; third antiretroviral agent remains the 
same (n=250)
Since different antiretroviral third agents require different doses of TAF, randomization will be 
stratified by  [CONTACT_662165]: boosted protease inhibitors vs. other agents. 
FffAF 
Protocol GS-US-311-1717 Final 
[COMPANY_009] Sciences, Inc. Original 
Table 3-1. Recomme nded F/TAF dose by [CONTACT_3252]-admin istered third agent: 
TI·eatment Arm [ADDRESS_893146] Agents 
FffAF (200/10 mg) LPV/r, ATV+RTV , ATV+COBI (or ATVICOB I FDC), DRV+RTV, 
DRV+COBI (or DRV/COBI FDC) 
FffAF (200/25 mg) EFV, RPV, RAL, DTG, MVC, NVP 
Figure 3-1. Study Schema 
Day 1• Week48 
(Primary Endpoint) 
Screening: 
~ 30 days 
prior to 
Day 1 Treatment Arm 1: 
F/TAF +placebo -to-match ABC/3TC (n= 250) 
Treatment Arm 2: 
ABC/3TC + P lacebo-to-match FffAF (n= 250) Week 
96 Unblinding 
V .. b,c 
lSlt 30 
Day 
a Following the Day 1 visit, subjects will rettu11 for study visits at Weeks 4, 8, 12, and then evety 12 weeks tlu·ough Week 96. 
b Aftet· Unblinding visit, in cotmtries whet·e FIT AF FDC is not conuuercially available , subjeds (except in certain cotmtries 
such as [LOCATION_006]) will be given the option to receive the open-label F/TAF FDC and attend study visits every 12 weeks tultil it 
bec.omes conuuercially available, or until [COMPANY_009] Sciences temlinates the study in that countJ.y. Subjects who complete the 
study tlu·ough Unblinding and do not wish to continue to participate (including all subjects in certain cotmtries such as [LOCATION_006]) 
will be required to rettu11 to tl1e clinic [ADDRESS_893147] discontinued stt1dy drug before Week 96 will not be eligible for the extension phase of the study; these 
subjects will be asked to continue attending the scheduled stt1dy visits tlu-ough Unblinding. 
3.4. Duration of Treatment 
The treatment dmation is [ADDRESS_893148] been unblinded. After unblinding, in countries where F/TAF FDC is n ot 
commercially available, subjects (except in ce1tain countries such as [LOCATION_006]) will be given the 
option to receive the open-label F/TAF FDC and attend study visits every 12 weeks until it 
becomes commercially available, or until [COMPANY_009] Sciences te1minates the study in that country. 
Subjects who complete the study through Unblinding Visit and do not wish to receive open-label 
FITAF FDC will be required to retmn to the clinic for a 30-Day Follow Up visit. 
CONFIDENTIAL Page 33 11 March 2015 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page34 11 March 2015After the Unblinding Visit, subjects in certain countries (eg [LOCATION_006]) per requirement must stop 
taking stud y drug and co mplete a 30-Day Follow Up visit.
3.5. Biomarker Testing
3.5.1. Samples for Optional Future Research
In addition to the study -specific informed consent to be signed b y each subject participating in 
the study, a separate, specific signature [CONTACT_22862] a sub ject's agreement to 
provide additional samples or to allow the use of the remainder of their already collected PK 
specimens for optional future research, once approved by  [CONTACT_662166]. 
The specime ns collected for optional future research will be used to increase our knowledge and 
understanding of the biology  of the study  disease and related diseases and to study  the 
association of biomarkers with disease pathogenesis, progression and/or treatment o utcomes, 
including efficacy , adverse events, and the processes of drug absorption and disposition. These 
specimens may  be used also to develop biomarker or diagnostic assay s and establish the 
performance characteristics of these assay s. The collection and analysis of optional future 
research specimens will facilitate the rational design of new pharmaceutical agents and the 
development of diagnostic tests, which may  allow for individualized drug therapy  for patients in 
the future.
F/TAF
Protocol GS -US-311-[ADDRESS_893149] be obtained 
prior to initiation of study procedures
2.Age ≥ 18 years
3.Currently  receiving antiretroviral regimen containing ABC/3TC FDCin combination with 
one third agent for 6consecutive months prior to Screening. Refer toTable4-
[ADDRESS_893150] age nts of the pre -existing regimen ; ABC/3TC/DTG (Triumeq®FDC) is not an 
allowed pre -existing regimen
4.Plasma HIV -1 RNA levels < 50 copi[INVESTIGATOR_014]/mL  for ≥ 6 months preceding the screening visit 
(measured at least twice using the same assay ) and not experienced two consecutive HIV-1 
RNA above detectable levels after achieving a confirmed (two consecutive) HIV -[ADDRESS_893151] y ear
To determine virologic suppre
ssion in the preceding 6 months prior to screening, the lower 
limit of quantification (LLOQ) b y the local HIV -1 RNA assay  may be used, only  if its LLOQ 
is greater than 50 copi[INVESTIGATOR_014]/ mL (e.g. LLOQ of 75 copi[INVESTIGATOR_014]/mL )
5.Plasma HIV -1 RNA levels < 50 copi[INVESTIGATOR_014]/mL  at Screening Visit
6.Normal ECG (or if abnormal, determined b y the Investigator to be not clinically significant)
7.Estimated GFR ≥ 50 mL /min according to the Cockcroft Gault formula for creatinine 
clearance { 2202}:
Male: (140–age in years) (wt in kg) CLcr (mL/min)
72(serum creatinine in mg/dL)
Female: (140–age in years) (wt in kg) 0.85 CLcr (mL/min)
72(serum creatinine in mg/dL)
8.Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page36 11 March [ZIP_CODE].Total bilirubin ≤ 1.5 mg/dL , or normal direct bilirubin (subjects with documented Gilbert’s 
syndrome or with atazanavir -associated hy perbilirubinemia may  have total bilirubin up to [ADDRESS_893152])
10.Adequate hematologic function (absolute neutrophil count ≥1,000/mm3; platelets 
≥50,000/mm3; hemoglobin ≥ 8.5 g/dL)
11.Serum amy lase ≤ 5 × ULN (subjects with serum amy lase > 5×ULN will remain eligible if 
serum lipase is ≤ 5 ×ULN)
12.A female subject is eligible to enter the stud y if it is confirmed that she is:
a.Not pregnant or nursing
b.Of non-childbearing potential (e.g. , women who have had a hy sterectomy , have had both 
ovaries removed or medically  documented ovarian failure, or are postmenopausal women 
> 54years of age with cessation (for 12months) of previousl y occurring menses) .
c.Of childbearing potential (as defined in Appendix 5)and agrees to utilize highly effective 
contraception methods or be non -heterosexually  active or practice sexual abstinence 
(asdefined in Appendix 5)from screening throughout the duration of study treatment and 
for [ADDRESS_893153] agree to utilize a highl y effective method of contraception (as defined in 
Appendix 5) during heterosexual intercourse or be non -heterosexually active, or practice 
sexual abstinence from first dose throughout the study  period and for [ADDRESS_893154] udy drug dose.
Table4-1. Allowable Antiretroviral Agents of Pre -Existing Regimen
Antiretroviral Class Agents
Boosted PI[INVESTIGATOR_662148]/r, ATV+RTV, ATV+COBI (or ATV/ COBI FDC ),  
DRV+RTV, DRV+COBI (or DRV/ COBI FDC )
NNRTI EFVa, RPVa, NVP
INSTI RAL, DTGa
CCR5 inhibitor MVC
aDTGisallowed only when administered as an individual agent, but not as part of single tablet regimen (i.e. ABC/3TC/DTG)
bChange of pharmacoenhancer between RTV and COBI in itself, including change from PI+RTV to PI/ COBI, is not 
considered as change of regimen
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page37 11 March [ZIP_CODE].3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1.A new AIDS -defining condition diagnosed within the 30 day s prior to screenin g 
(exceptCD4cell count and/or percentage criteria) (refer to Appendix 6)
2.Hepatitis B surface antigen (HBsAg) positive
3. Subjects experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)
4. Subjects receiving ongoing treatment with bisphosphonate to treat bone disease 
(e.g.osteoporosis)
5.
Females who are breastfeeding
6.Positive serum pregnancy test 
7.Have an implanted defibrillator or pacemaker
8.Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
subject study  compliance
9.A history of malignancy  within the past 5 y ears (prior to screening) or ongoing malignancy  
other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non- invasive 
cutaneous squamous carcinoma. Subjects with cutaneo us KS are eligible, but must not have 
received an y systemic therapy  for KS within [ADDRESS_893155] not be 
anticipated to require s ystemic therap y during the study
10.Active, serious infections (other than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap y within [ADDRESS_893156] unsuitable for the stud y or unable to comply with dosing requirements
12.Participation in any  other clinical trial (including observational trials) without prior approval 
from the sponsor is prohibited while participating in this trial
13.Medications ex cluded due to the potential for interaction with FTC, TAF, ABC or 3TC 
(Table5-2). Administration of an y Prohibited Medication ( Table5-2) must be discontinued 
at least 30 day s prior to the Day  1 visit and for the duration of the study . Use of Medications 
to Be Used With Caution ( Table5-2) are allowed and are at the discretion of the Principal 
Investigator.
F/TAF
Protocol GS -US-311-[ADDRESS_893157] number using 
Interactive Web Response Sy stem (IWRS). Once a subject number has been assigned to a 
subject, it will not be reassigned to an y other subject. The subject number assignment and 
randomizatio n may be performed up to [ADDRESS_893158] eligibility  has been confirmed. 
Subjects will be randomized in a 1:[ADDRESS_893159] agents (boosted protease inhibitors vs. any other 
protocol allowed third agents) in a subject’s existing regimen.
Treatment Arm 1 : F/TAF + Placebo -to-match ABC/3TC; thethird ARVagent(as prescribed 
by [CONTACT_18413]) of the subjects’ regimen should remain the same during the subjects’ 
participation in the study (n=250)
Treatment Arm 2 : ABC/3TC + Placebo -to-match F/TAF; the third ARV agent (as prescribed 
by [CONTACT_737]) of the subjects’ regimen should re main the same during the subjects’ 
participation in the study  (n=250)
IWRS will assign blinded study  drug bottle numbers at each study  visit until the Unblinding 
Visit. Study  drug will be dispensed to the subject in a blinded fashion. All Day1 visit tes ts and 
procedures must be completed prior to the administration of the first dose of the study 
drug.Initiation of treatment with the study  drug must take place within [ADDRESS_893160] be clearly explained in source documentation and on the electronic case report 
form (eCRF), along with the date on which the treatment assignment was obtained. The 
investigator is requested to contact [CONTACT_337351] y treatment 
unblinding .
F/TAF
Protocol GS -US-311-[ADDRESS_893161]’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
so is specificall y withdrawn by [CONTACT_423].
[COMPANY_009]Drug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs).
5.2. Description and Hand ling
5.2.1. Formulation
[IP_ADDRESS]. Emtricitabine/Tenofovir Alafenamide (F/TAF) Tablets and matching placebo
For subjects randomized to Treatment Arm 1, F/TAF and placebo -to-match F/TAF tablets will 
be provided b y the Sponsor. Emtricitabine /Tenofovir Alafenamide 200/25 mg tablets are 
rectangular -shaped, film -coated blue tablets and are debossed with "GSI" on one side of the 
tablet and "225" on the other side of the tablet. The F/TAF tablet cores contain 200 mg of 
emtricitabine and 25 mg of tenofovir alafenamide. I n addition to the active ingredients, the 
F/TAF tablets contain croscarmellose sodium, magnesium stearate, and microcry stalline 
cellulose. The tablet cores are film -coated with Blue #2/indigo carmine aluminum lake, 
polyethylene glycol, polyviny l alcohol, talc, and ti tanium dioxide.
Emtricitabine /Tenofovir Alafenamide 200/10 mg tablets are rectangular -shaped, film -coated 
gray tablets and are debossed with "GSI" on one side of the tablet and "210" on the other side of 
the tablet. The F/TAF tablet cores contain 200 mg o f emtricitabine and 10 mg of tenofovir 
alafenamide. In addition to the active ingredients, the F/TAF tablets contain croscarmellose 
sodium, magnesium stearate, and microcry stalline cellulose. The tablet cores are film- coated 
with iron oxide black, poly ethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Placebo-to-match F/TAF 200/25 mg tablets are rectangular- shaped, film -coated blue tablets and 
are debossed with "GSI" on one side of the tablet and "225" on the other side of the tablet. 
Placebo tablets contain croscarmellose sodium, magnesium stearate, lactose and microcry stalline 
cellulose. The tablet cores are film -coated with Blue #2/indigo carmine aluminum lake, 
polyethylene glycol, polyviny l alcohol, talc, and titanium dioxide.
Placebo-to-match F/TAF 200/10 mg tablets are rectangular- shaped, film -coated gray  tablets and 
are debossed with "GSI" on one side of the tablet and "210" on the other side of the tablet. 
Placebo tablets contain croscarmellose sodium, magnesium stearate, lactose and micr ocrystalline 
cellulose. The tablet cores are film -coated with iron oxide black, poly ethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page40 11 March [ZIP_CODE].2.1.2. Abacavir/Lamivudine (ABC/3TC ) and matching placebo
Abacavir/Lamivudine (ABC/3TC) tablets are commerciall y sourced. Information regarding the 
formulation of commercially  available Abacavir/Lamivudine (ABC/3TC) can be found in the 
current prescribing information. 
Placebo-to-match Abacavir/L amivudine (ABC/3TC) tablets are capsule -shaped, film -coated 
orange tablets and are debossed with “GS FC2” on one side of the tablet and plain faced on the 
other side of the tablet. Placebo tablets are identical in appearance to the active tablets . Placebo 
tablets contain croscarmellose sodium, magnesium stearate, lactose and microcrystalline 
cellulose. The tablet cores are film -coated with Yellow #6/sunset y ellow FCF aluminum lake,
polyethylene glycol, polyviny l alcohol, talc, and titanium dioxide.
5.2.2. Packaging and Labeling
Emtricitabine/Tenofovir Alafenamide (F/TAF) tablets and placebo -to-match F/TAF tablets are 
packaged in a white high density  polyethylene (HDPE) bottle. Each bottle contains 30 tablets, 
silica gel desiccant, and poly ester packing material. Each bottle is enclosed with a white, 
continuous thread, child -resistant poly propylene screw cap fitted with an induction- sealed and 
aluminum -faced liner.
Abacavir/Lamivudine (ABC/3TC) tablets and placebo -to-match 
ABC/3TC tablets are packag ed 
in a white high density  polyethylene (HDPE) bottle. Each bottle contains [ADDRESS_893162] identification, the drug should not be stored in a container other than the container in 
which it is supplied.
Study drug(s) bottles to be distributed to centers in the US and EU shall be labeled to meet all 
applicable requirements of the US Food and Drug Administration (FDA), EU Guideline to Good 
Manufacturing Practice -Annex 13 (I nvestigational Medicinal Products), and/or other local 
regulations as applicable.
5.2.3. Storage and Handling
Emtricitabine /Tenofovir Alafenamid e  and the placebo- to-match Emtricitabine/Tenofovir 
Alafenamide tablets should be stored at a controlled room temperature of 25 °C (77 °F); 
excursions are permitted between 15 °C and 30 °C (59 °F and 86 °F). Storage conditions are 
specified on the label. 
Abacavir/Lamivudine (ABC/3TC) and the placebo- to-match Abacavir/Lamivudine (ABC/3TC) 
tablets should be stored at a controlled room temperature of 25 °C (77 °F); excursions are 
permitted between 15 °C and 30 °C (59 °F and 86 °F). Storage conditions are spec ified on the 
label.
F/TAF
Protocol GS -US-311-[ADDRESS_893163] ARV agent of the subje cts’ pre-existing regimen should be stored according to the 
approved product labeling for each particular component.
5.3. Dosage and Administration
F/TAF, placebo -to-match F/TAF, ABC/3TC and placebo -to-match ABC/3TC fixed -dose 
combination tablets will be provid ed by [CONTACT_10869]. The third antiretroviral agent of the 
subjects’ pre -existing regimen will be prescribed by  [CONTACT_737], and the subject is 
responsible for obtaining the third ARV agent prior to Day  1 visit.As both F/TAF and ABC/3TC 
can be take n without regard to food, subjects should be instructed to comply  with the food or 
fasting requirements of the third agent, if an y.
Treatment Arm 1 : F/TAF FDC tablet (200/10 mg or 200/2 5 mg) + placebo -to-match ABC/3TC
FDC tablet in combination with a third antiretroviral agent administered orally  once daily  (QD) 
(at approximately  the same time every  day)with the recommended dose by  [CONTACT_3252]-administered third 
agent as summarized below.
Table5-1. Recommended F/TAF Dose by [CONTACT_15957]- administered Third A gent
Treatment Arm [ADDRESS_893164] Agents
F/TAF (200/10 mg) LPV/r, ATV+RTV, ATV+COBI (or ATV/ COBI FDC ),  
DRV+RTV, DRV+COBI (or DRV/ COBI FDC )
F/TAF (200/25 mg) EFV, RPV, RAL, DTG, MVC, NVP
Treatment Arm 2 : Current antiretroviral drug regimen containing ABC/3TC + placebo -to-match 
F/TAF FDC tablet in combination with a third antiretroviral agent administered orally , QD (at 
approximately  the same time each day )
Subjects will be instructed to bring all stud y medication in the original container at each clinic 
visit for drug accountability  (unless otherwise specified in the study  procedures sections of this 
protocol). 
Antiretroviral agents that are not specified in Table5-1will be prohibi ted. 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page42 11 March [ZIP_CODE].4. Prior and Concomitant Medications
The use of medications for the treatment of HIV, other than the study  treatment (i.e. F/TAF or 
ABC/3TC ) and baseline third agent is prohibited. Medications listed in the following table and 
use of herbal/natural supp lements are excluded or should be used with caution while subjects are 
participating in the stud y due to potential drug -drug interactions with the study  drugs.
Table5-2. Prior and Concomitant Medications
Medications to be avoided and medications to be used with caution due to the potential for 
drug-drug interaction with FTC, TAF, ABC or 3TC are as follows:
Medication Class Prohibited Medications Medications to be used with caution
Antiarrhythmicsamiodarone, quinidine: May increase 
concentration of TAF and/or TFV
AntibacterialsTrimethoprim/Sulfamethoxazole
(160/800 mg):
TMP/SMX increases the exposure of 
lamivudine.
Anticonvulsantscarbamazepi[INVESTIGATOR_050], oxcarbazepi[INVESTIGATOR_050], 
phenobarbital, phenytoin
Antifungalsitraconazole, ketoconazole, voriconazole:
may increase concentration of TAF and/or
TFV
Antimycobacterials rifabutin, rifampin, rifapentineclarithromycin: may increase concentration
of TAF and/or TFV
BisphosphonateAny agent in this class (for example:
alendronate, ibandronate, risedronate,
zoledronate, pamidronate, teriparatide)
Calcium channel 
blockersdiltiazem, felodipi[INVESTIGATOR_050], verapamil: may
increase concentration of TAF and/or TFV
DigoxinConcomitant use may result in an increased
or decreased digoxin concentration; use with 
caution and with appropriate monitoring of 
serum digoxin concentrations.
EthanolEthanol:
Ethanol decreases the elimination of abacavir 
causing an increase in overall ABC exposure
Herbal/Natural 
SupplementsSt. John’s wort (Hypericum perforatum), 
Echinacea, Milk thistle (i.e. silymarin), 
Chinese herb sho -saiko-to (or Xiao -Shai-Hu-
Tang)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page43 11 March 2015Medication Class Prohibited Medications Medications to be used with caution
MethadoneMethadone:
Coadministration of ABC with methadone 
increases oral methadone clearance
This alteration will not result in a methadone 
dose modification in the majority of patients; 
however, an increased methadone dose may 
be required in a small number of patients.
Other probenecid
Should subjects have a need to initiate treatment with any  excluded concomitant medication, the 
[COMPANY_009] Medical Monitor must be consulted prior to initiation of the new medication. In instances 
where an excluded medication is initiated prior to discussion with the Sponsor, the Investigator 
must notify  [COMPANY_009] Sciences as soon as he/she is aware of the use of the excluded medication.
Additionally , Investigators should refer to the product/package inserts of the other antiretroviral 
medications for contraindications related to their use.
5.5. Changes in Antiretroviral Therapy
Prior to the Unblinding Visit and during the open- label extension phase of the study , subjects and 
Investigators are not permitted from changing the third agent.
5.6. Dispensing and Accountability of Investigational Medicinal Product (IMP)
The Investigator is responsible fo r ensuring adequate accountability  of all used and unused IMP.
The Investigator [or designee (e.g., stud y center pharmacist)] will acknowledge receipt of the 
study drugs from [COMPANY_009] Sciences (or designee) after reviewing the shipment’s content and 
condition. The Investigator (or designee) will be responsible for maintaining an accurate 
inventory  (on IMP accountability  records) of the dates and quantities of all study  drugs received, 
dispensed, and returned. Each dose of the study  drug administered at the st udy center will be 
administered b y qualified study center personnel. All doses of study drug administered to 
subjects in the clinic under the supervision of staff will be accuratel y recorded on the 
Investigational Product Inventory  Logs provided by  [CONTACT_433811] (or on equivalent 
documentation maintained by  [CONTACT_90267]), which indicates the date and quantity  of all doses 
of study drug(s) dispensed to individual subjects. The requirements of all applicable Federal and 
State drug dispensing laws will a pply to all doses of study  drugs dispensed by  [CONTACT_737] 
(or designee). 
The IMP inventory  and dispensing logs must be available for inspection by [CONTACT_10184]. 
Study medication supplies, including partiall y used or empty bottles, must be accoun ted for by 
[CONTACT_662167].
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page44 11 March 2015IMPaccountability  records will be provided to each study  site to:
Record the date received and quantity  of IMPkits
Record the date, subject number, subject initials, the IMPkit number dispensed
Record the date, quantity of used and unused IMPreturned, along with the initials of the 
person recording the information.
5.7. I nvestigational M edicinal Product Return or Disposal
[COMPANY_009] recommends that used and unused IMP supplies be returned to the shippi [INVESTIGATOR_10803]. The stud y monitor will provide instructions for return. If 
return is not possible, the study  monitor will evaluate each study  center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
[COMPANY_009] QA, the site may  destroy used (empt y or partially empty) and unused I MP supplies in 
accordance with that site ’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files. 
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP 
destroyed. Records must show the identification and quantity  of each unit destr oyed, the method 
of destruction, and the person who disposed of the I MP. Upon study  completion, copi[INVESTIGATOR_143346]. Another copy  will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
F/TAF
Protocol GS -US-311-[ADDRESS_893165]’s clinical chart and 
appropriate eCRFs. In addition, the Sponsor or Contract Research Organization (CRO) should be 
promptly notified of an y protocol deviations.
6.1. Subject Enrollment and Treatment Assignment
It is the responsibi lity of the Investigator to ensure that subjects are eligible for study  prior to 
enrollment. Please refer to Section 5for details about randomizati on and treatment assignment.
6.2. Pretreatment Visit Assessments
6.2.1. Screening Visit
Subjects will be screened within 30 daysbefore Day 1 visitto determine eligibility  for 
participation in the study . The following will be performed and documented at screening:
[IP_ADDRESS]. Obtain written informed consent
[IP_ADDRESS]. Obtain medical history including history  of HIV-1 disease-related events and 
prior medications within 30 day s of the Screening visit
[IP_ADDRESS]. Complete phy sical examination(urogenital/anorectal exams will b e performed at 
the discretion of the Investigator)
[IP_ADDRESS]. V ital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature) , body weight, 
and height
[IP_ADDRESS]. 12- lead ECG performed supi[INVESTIGATOR_050]
[IP_ADDRESS]. Urine collection for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis and urine chemistry
[IP_ADDRESS]. Blood sample collection for the following laboratory  analyses:
[IP_ADDRESS].1. Serum pregnancy  test (females of childbearing potential only ). If the test is 
positive, the subject will not be enrolled.
[IP_ADDRESS].2. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and 
indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid, and am ylase (reflex lipase testing is performed in subjects with total amy lase 
1.5 
ULN)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page46 11 March [ZIP_CODE].[IP_ADDRESS]. Estimated GFR according to the Cockcroft Gault formula for creatinine clearance:
i.Male: (140 –age in years) (wt in kg) = CLcr (mL/min)
72 (serum creatinine in mg/dL)
ii.Female: (140 –age in years) (wt in kg) 0.85 = CLcr (mL/min)
72 (serum creatinine in mg/dL)
[IP_ADDRESS].4. Hematology  profile: complete blood count (CBC) with differential and platelet 
count
[IP_ADDRESS].5. CD4+ cell count
[IP_ADDRESS].6. Plasma HI V-1RNA 
[IP_ADDRESS].7. Hepatitis B surface antigen (HBsAg) serology
[IP_ADDRESS]. Record an y serious adverse events and all adverse eventsrelated to protocol 
mandated procedures occurring after signing of the consent form.
Subjects meeting al l of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 
[ADDRESS_893166] all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse events electronic case report form 
(eCRF).  All other untoward medical occurrences observed during the screening period, 
including exacerbation or changes in medical historyare to be captured on the medical history  
eCRF.  See Section7AdverseEvents and Toxicity  Manageme nt for additional details.
6.2.2. Day 1Visit
The following evaluations are to be completed at the Day  [ADDRESS_893167] within 24 hours after the Day 1 visit.
[IP_ADDRESS]. DXA Scan (spi[INVESTIGATOR_35632])
[IP_ADDRESS].1. The DXA scan will be performed on subjects once eligibility  is confirmed and 
prior to study  drug administration at the Day  1 Visit.  The scan may  be performed 
prior to or on th e Day1 Visit so long as it occurs before dosing
[IP_ADDRESS]. Review of AEs and changes in concomitant medications
[IP_ADDRESS]. Complete phy sical examination (urogenital/anorectal exams will be performed at 
the discretion of the Investigator)
[IP_ADDRESS]. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page47 11 March [ZIP_CODE].2.2.5. Urine collection for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis and urine chemistry  
[IP_ADDRESS].2. Evaluations of renaltubular function (collected fasted): If the subject has not 
fasted prior to the visit, the visit may  proceed, but the subject must return within 
72 hours in a fasted state to provide a urine sample for these evaluations.
[IP_ADDRESS].3. Urine pregnancy  test (females of childbearing potential only ). If the urine 
pregnancy  test is positive at Day  [ADDRESS_893168] will not be able to participate.
[IP_ADDRESS].4. Urine sample storage for possible additional clinical testing
[IP_ADDRESS]. Blood sample collection for the following laboratory  analyses:
[IP_ADDRESS].1. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and 
indirect bilirubin, total prot ein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid, and am ylase (reflex lipase testing is performed in subjects with total amy lase 
1.5UL
N)
[IP_ADDRESS].2. Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours 
prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct 
LDL, and triglycerides). If the subject has not fasted prior to the visit, the visit 
may proceed, but the subject must return within 72 hours in a fasted state to draw 
blood for the metabolic assessments.
[IP_ADDRESS].3. Estimated GFR, according to the Cockcroft Gault formula for creatinine clearance
[IP_ADDRESS].4. Hematology  profile: CBC with differential and platelet count
[IP_ADDRESS].5. Plasma HI V-1RNA 
[IP_ADDRESS].6. CD4+ cell count
[IP_ADDRESS].7. Hepatitis C virus antibody  (HCVAb) serology . If the antibody  test result is 
positive, HCV RNA test will be performed to confirm HCV viremia
[IP_ADDRESS].8. Plasma sample storage for virology , safety, and/or PK testing 
[IP_ADDRESS].9. Serum sample storage for possible additional clinical testing (for subjects who 
provide consent)
[IP_ADDRESS].10 .Evaluations of b oneturnover(collected fasted): If the subject has not fasted prior 
to the visit, the visit m ay proceed, but the subject must return within 72 hours in a 
fasted state to draw blood for theseevaluation s
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page48 11 March [ZIP_CODE].[IP_ADDRESS]. Evaluations of inflammation, including but not limited to cy statin-C, IL 6, hs 
CRP, d-dimer, sCD14, and sCD163
[IP_ADDRESS].12. Evaluations of platelet function, including but not limited to soluble glycoprotein 
VI (sGPVI), P -selectin, and soluble CD40 ligand
[IP_ADDRESS].13. Platelet function for substudy  subjects (onl y at selected sites)
[IP_ADDRESS].14. Whole blood sample storage for virology  analyses
[IP_ADDRESS]. Obtain subject number and randomize the subject via the I WRS. The subject 
number assignment may  be performed up to [ADDRESS_893169] 
eligibility  has been confirm ed
[IP_ADDRESS]. Study drug dispensation: Investigators must provide a prescription to the subjects 
for the third ARV agent in their pre -
existing regimen. The subject is responsible 
for obtaining the third ARV prior to or during the study  visit
[IP_ADDRESS].1. Study drug will be dispensed in a blinded fashion
[IP_ADDRESS].2. All subjects will take2 tabletsdaily, in addition to the third ARV agent
[IP_ADDRESS].3. Subjects must initiate dosing of stud y drug within 24 hours after the Da y 1 visit
[IP_ADDRESS]. Subjects should also be counseled regarding the importance of adherence and 
taking their stud y medications in the morning at approximately  the same time 
each day
For subjects in German y, DXA scans will not be performed at an y study visit.
6.3. Treatment Assessments
6.3.1. Treatment Visits (Weeks 4 
– 48)
The following evaluations are to b e completed at the end of Weeks4, 8, 12, 24, 36 and48 unless 
otherwise specified .
All study visits are to be scheduled relative to the Day 1 visit date. Studyvisits are to be 
completed w ithin ± 2days of the protocol -specified visit date based on the Day1 visit through 
Week12and completed within ± 6days of the protocol -specified visit date through Week 36,
unless otherwise specified.  The visit window at Week 48 will be ± 6weeks of t he 
protocol-specified visit date, and this clinical visit window coincides with the Week 48 statistical 
analysis window for HIV RNA.
Regularly  scheduled evaluations will be made on all subjects whether or not they  continue to 
receive study  drug.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page49 11 March [ZIP_CODE].3.2.1. DXA Scans (spi[INVESTIGATOR_35632]) ( Weeks 24 and 48 ;can be performed ≤10 days 
beforestudyvisit)
[IP_ADDRESS]. Review of AEs and changes in concomitant medications
[IP_ADDRESS]. Complete phy sical examination ( Weeks 24 and 48 ) (urogenital/anorectal exams 
will be performed at the discretion of the Investigator)
[IP_ADDRESS]. Symptom-directed phy sical examination as needed ( Weeks 4, 8, 12, 36)
[IP_ADDRESS]. 12-lead ECG performed supi[INVESTIGATOR_050] (Week 48 only)
[IP_ADDRESS]. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), incl uding 
weight
[IP_ADDRESS]. Urine collection for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis and urine chemistry  
[IP_ADDRESS].2. Evaluations of renaltubular function (collected fasted): If the subject has not 
fasted prior to the visit, the visit may  proceed, but the subject must return within 
72 hours in a fasted state to provide a urine sample for these evaluations. 
(Weeks4, 12, 24 and 48)
[IP_ADDRESS].3. Urine pregnancy  test (females of childbearing potential only); positive urine 
pregnancy  tests will b e confirmed with a serum test. I
f the test is positive, the 
subject will be discontinued.
[IP_ADDRESS].4. Urine sample storage for possible additional clinical testing
[IP_ADDRESS]. Blood sample collection for the following laboratory  analyses:
[IP_ADDRESS].1. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and 
indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid, and am ylase (reflex lipas e testing is performed in subjects with total amy lase 
1.5ULN). At Weeks 24 and 48, analyses of glucose will be done as part of 
the fasting metabolic assessments and not as part of the chemistry profile. 
[IP_ADDRESS].2. Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours 
prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct 
LDL, and triglycerides). If the subject has not fasted prior to the visit, the visit 
may proceed, but the subject must return within 72 hours in a fasted state to draw 
blood for the metabolic assessments ( Weeks 24 and 48 only )
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page50 11 March [ZIP_CODE].[IP_ADDRESS]. Estimated GFR, according to the Cockcroft Gault formula for creatinine clearance
[IP_ADDRESS].4. Hematology  profile: CBC with differential and platel et count
[IP_ADDRESS].5. Plasma HIV -1 RNA 
[IP_ADDRESS].6. CD4+ cell count
[IP_ADDRESS].7. Plasma sample storage for virology , safetyand/or PK testing 
[IP_ADDRESS].8. Serum sample storage for possible additional clinical testing (for subjects who 
provide consent)
[IP_ADDRESS].9. Evaluations of b oneturnover(collected fasted): If the subject has not fasted prior 
to the visit, the visit may  proceed, but the subject must return within 72 hours in a 
fasted state to draw blood for these evaluations. ( Weeks 4, 12, 24 and 48 )
[IP_ADDRESS].10. Evaluations of inflammation, including but not limited to cy statin-C, IL 6, hs 
CRP, d-dimer, sCD14, and sCD163 (Weeks4, 
12, 24 and 48)
[IP_ADDRESS].11. Evaluations of platelet function, including but not limited to soluble glycoprotein 
VI (sGPVI), P-selectin, and soluble CD40 ligand 
(Weeks4, 12, 24 and 48)
[IP_ADDRESS].12 Platelet function for substudy  subjects (onl y at selected sites) (Weeks 4 and 12)
[IP_ADDRESS].13 Single whole blood sample collection ( Week 4 only ): PBMC sample processing 
will be performed b y the central laboratory ; TFV-DP concentrations in PBMCs 
will be determined. 
[IP_ADDRESS]. Pharmacokinetic Blood Collection:
[IP_ADDRESS].1. A single PK blood sample should be collected as part of the safet y laboratory 
blood draws at an ytime pre-or post-dose (Weeks 8, 12, 24and 36)
[IP_ADDRESS].2.
A single PK blood sample will be collected after an observed in- clinic dose 
15minutes to [ADDRESS_893170] dose (Weeks 4 and 48 only ).
Subjects may  take their previous day ’s dose at t heir regular dosing time.  
Subjects should be reminded not to take their dose of study  medication prior 
to their clinic visit; instead, subjects should bring their dose of study  
medication to the 
clinic
If the subject has taken their dose of stud y drugs prior to the visit, the visit 
may proceed, but the subject must return with [ADDRESS_893171]-dose PK collection
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page51 11 March [ZIP_CODE].3.2.10. Subjects who meet the criteria for virologic rebound should be managed 
according to Management of Virologic Failure ( Section6.9)
[IP_ADDRESS]. Document study  drug dispensation and accountability  for all study  drugs 
dispensed
6.3.2. Treatment Visits (Weeks 60-
96)
The following evaluations are to be completed at the end of Weeks 60, 72, 84, and 96 unless 
otherwise specified .
Study visits are to be completed within ± 6days of the protocol -specified visit date through 
Week84 unless otherwise specified. The visit window at Week 96 will be ± 6weeks of the 
protocol-specified visit d
ate, and this clinical visit window coincides with the Week 96 statistical 
analysis window for HIV RNA. 
Regularly  scheduled evaluations will be made on all subjects whether or not they  continue to 
receive study  drug.
[IP_ADDRESS]. DXA Scans (spi[INVESTIGATOR_35632]) ( Weeks 72 and 96; can be performed ≤10 days 
beforestudyvisit) 
[IP_ADDRESS]. Review of AEs and changes in concomitant medications
[IP_ADDRESS]. Complete phy sical examination ( Weeks 72 and 96 ) (urogenital/anorectal exams 
will be performed at the discretion of the Investigator)
[IP_ADDRESS]. Symptom-directed phy sical examination as needed ( Weeks 60 and 84 )
[IP_ADDRESS]. 12 lead ECG performed supi[INVESTIGATOR_050] ( Week 96)
[IP_ADDRESS]. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
[IP_ADDRESS]. Urine collec tion for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis and urine chemistry  
[IP_ADDRESS].2. Evaluations of renaltubular function (collected fasted): If the subject has not 
fasted prior to the visit, the visit may  proceed, but the subject must retu rn within 
72 hours in a fasted state to provide a urine sample for these evaluations. 
(Week72 and 96)
[IP_ADDRESS].3. Urine pregnancy  test (females of childbearing potential only); positive urine 
pregnancy  tests will be confirmed with a serum test. I f the testis positive, the 
subject will be discontinued.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page52 11 March [ZIP_CODE].[IP_ADDRESS]. Urine sample storage for possible additional clinical testing
[IP_ADDRESS]. Blood sample collection for the following laboratory  analyses:
[IP_ADDRESS].1. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and 
indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid, and am ylase (reflex lipase testing is performed in subjects with total amy lase 
1.5ULN).At Weeks 72 and 96, analyses of glucose will be done as part of 
the fasting metabolic assessments and not as part of the chemistry profile
[IP_ADDRESS].2. Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours 
prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct 
LDL, and trigly cerides).If the subject has not fasted prior to the visit, the visit 
may proceed, but the subject must return within 72 hours in a fasted state to draw 
blood for the metabolic assessments (Weeks 72 and 96)
[IP_ADDRESS].3. Estimated GFR, according to the Cockcroft- Gault formula for creatinine clearance
[IP_ADDRESS].4. Hematology  profile: CBC with differential and platelet count
[IP_ADDRESS].5. Plasma HIV -1 RNA 
[IP_ADDRESS].6. CD4+ cell count
[IP_ADDRESS].7. Plasma sample storage for virology , safetyand/or PK testing 
[IP_ADDRESS].8. Serum sample storage for possible additional clinical testing (for subjects who 
provide consent)
[IP_ADDRESS].9. Evaluations of b oneturnover(collected fasted): If the subject has not fasted prior 
to the visit, the visit may  proceed, but the subject must return within 72 hours in a 
fasted state to draw blood for these evaluations. ( Weeks 72 and 96 )
[IP_ADDRESS].10. Evaluations of inflammation, including but not limite d to cystatin-C, IL 6, hs 
CRP, d-dimer, sCD14, and sCD163 (Weeks72and 96)
[IP_ADDRESS].11 Evaluations of platelet function, including but not limited to soluble glycoprotein 
VI (sGPVI), P -selectin, and soluble CD40 ligand ( Weeks72and 96
)
[IP_ADDRESS]. Subjects w ho meet the criteria for virologic rebound should be managed 
according to Management of Virologic Failure Section 6.9
[IP_ADDRESS]. Document study  drug dispensation and accountability  for all study  drugs 
dispensed
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page53 11 March [ZIP_CODE].3.3. Treatment Visits (Post Week [ADDRESS_893172] 
Unblinding Visit)
After the Week [ADDRESS_893173] been unblinded, at which point they  will 
return for an Unblin ding Visit and will be given the option to receive open- label F/TAF. Study  
visits are to be completed within ±[ADDRESS_893174] Week 96 will be required to return for study  visits according to the 
schedule presented in Appendix 2Study Procedures Table and described in the text below.
[IP_ADDRESS]. The following evaluations are to be compl eted unless otherwise specified: DXA 
Scans (spi[INVESTIGATOR_35632]) ( every 24 weeks ;can be performed ≤ 10 days before study
visit) 
[IP_ADDRESS]. Review of AEs and changes in concomitant medications
[IP_ADDRESS]. Completed phy sical examination ( every 48 weeks ) (urogenital/anorectal exams 
will be performed at the discretion of the Investigator) or s ymptom-directed 
physical examination as needed (at all other visits)
[IP_ADDRESS]. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
[IP_ADDRESS].
12 lead ECG performed supi[INVESTIGATOR_050] ( every 48 weeks )
[IP_ADDRESS]. Urine collection for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis and urine chemistry  
[IP_ADDRESS].2. Urine pregnancy  test (females of childbearing potential only); positive urine 
pregnancy  tests will be confirmed with a serum test. I f the test is positive, t he 
subject will be discontinued
[IP_ADDRESS].3. Urine storage sample for possible additional clinical testing
[IP_ADDRESS].
Blood sample collection for the following laboratory  analyses:
[IP_ADDRESS].1. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and 
indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid, and am ylase (reflex lipase testing is performed in subjects with total amy lase 
1.5ULN).At visits post -Week 96 in which metabolic assessment is to be 
conducted, analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry profile
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page54 11 March [ZIP_CODE].[IP_ADDRESS]. Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours 
prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct 
LDL, and trigly cerides). If the subject has not fasted prior to the visit, the visit 
may proceed, but the subject must return within 72 hours in a fasted state to draw 
blood for the m etabolic assessments ( every 24 weeks ).
[IP_ADDRESS].3. Estimated GFR, according to the Cockcroft Gault formula for creatinine clearan ce
[IP_ADDRESS].4. Hematology  profile: complete blood count (CBC) with differential and platelet 
count
[IP_ADDRESS].5. Plasma HIV -1 RNA
[IP_ADDRESS].6. CD4+ cell count
[IP_ADDRESS].7. Plasma storage samples for virology, safety, and/or PK testing 
[IP_ADDRESS].8. Serum storage sam ple for possible additional clinical testing (for subjects who 
provide consent)
[IP_ADDRESS]. Subjects who meet the criteria for virologic rebound will be managed according to 
the Management of Virologic Failure Section6.9
[IP_ADDRESS]. Document study drug dispensa tion and accountability  for all study  drugs 
dispensed 
6.3.4. Unblinding Visit
Once [COMPANY_009] Sciences provides unblinded treatment assignments to the Investigators, allsubjects 
will return to the clinic (preferabl y within 30 days) for an Unblinding Visit. At the Unblinding 
Visit all subjects will discontinue their blinded study  drug and will be given the option to receive 
open-label F/TAF. 
If theF/TAF FDCis not commerciall y available in a country  in which the study  is being 
conducted, subjectswho complete the 96 weeks of the study  on randomly  assigned treatment 
will be given the option to receive the open-label F/TAF FDCand attend study  visits every  
12weeks until it becomes commerciall y available, or until [COMPANY_009] Sciences terminates the study  
in that country .
Subjects who do not wish to receive open- label F/TAF will discontinue their blinded study drug 
and will return for a [ADDRESS_893175] discontinued study  drug prior to the Unblinding Visit will not be eligible 
to 
receive open- label F/TAF ; these subjects will be asked to continue attending the scheduled study  
visits through the Unblinding Visit.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page55 11 March 2015Subjects in certain countries (such as the [LOCATION_006])will stop taking study  drug after the Unblinding 
Visit and re turn to the clinic 30 day s after the completion of study  drugs for a 30 -day Follow-Up 
Visit.
The following will be performed at the Unblinding Visit:
[IP_ADDRESS]. DXA Scan (spi[INVESTIGATOR_35632]) required if last scan was acquired > 12 weeks from the 
date of the Unbli nding Visit ( can be performed ≤ 10 days before studyvisit) 
[IP_ADDRESS].1. The DXA scan will be performed once unblinded treatment assignments have 
been provided and prior to administration of open- label study  drug (F/TAF) at the 
Unblinding Visit. The scan may be performed on the morning of the Unblinding 
Visit so long as it occurs before open -label study  drug dosing
[IP_ADDRESS]. Review of AEs and changes in concomitant medications
[IP_ADDRESS]. Complete phy sical examination (urogenital/anorectal exams will be perfor med at 
the discretion of the Investigator) 
[IP_ADDRESS]. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
[IP_ADDRESS]. 12- lead ECG performed supi[INVESTIGATOR_050]
[IP_ADDRESS]. Urine collection for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis and urine chemistry
[IP_ADDRESS].2. Urine pregnancy  test (females of childbearing potential only); positive urine 
pregnancy  tests will be confirmed with a serum test. I f the test is positive, the 
subject will not be able to participate in the open -label rollover stud y
[IP_ADDRESS].3. Urine storage sample for possible additional clinical testing
[IP_ADDRESS].
Blood sample collection for the following laboratory  analyses:
[IP_ADDRESS].1. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and
indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amy lase 
1.5ULN)
[IP_ADDRESS].2. Estimated GFR, according to the Cockcroft- Gault formula for creatinine clearance
[IP_ADDRESS].3. Hematology  profile: CBC with differential and platelet count
[IP_ADDRESS].4. Plasma HIV -1 RNA
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page56 11 March [ZIP_CODE].[IP_ADDRESS]. CD4+ cell count
[IP_ADDRESS].6. Plasma storage samples for virology , safetyand/or PK testing 
[IP_ADDRESS].7. Serum storage sample for possible additional clinical testing (for subjects who 
provide consent)
[IP_ADDRESS]. Document study  drug dispensation and accountability  for all study  drugs 
dispensed
[IP_ADDRESS].1. Subjects who wish to receive F/TAF will receive F/TAF (200/10 mg or 
200/25mg) based on the third ARV agent in their pre- existing regimen (see 
Table5-
1). 
6.4. Post-treatment Assessments
6.4.1. Early Study Drug Discontinuation (ESDD) Visit
If a subject discontinues study  drugprior totheUnblinding Visit ,  the subject will be asked to 
return to the clinic within 72 hours of stoppi[INVESTIGATOR_662149] y Study Drug 
Discontinuation (ESDD) visit. The subject will be asked to continue attending the scheduled 
study visits through the Unblinding Visit.
At the Early Study Drug Discontinuation Visit, any evaluations showing abnormal results 
indicating that there is a possible or probable causal relationship with the study drug , will 
be repeated weekly (or as often as deemed prudent by [CONTACT_737]) until the 
abnormality is resolved, returns to baselin e, or is otherwise explained.
The following evaluations are to be completed at the Earl y Study Drug Discontinuation Visit:
[IP_ADDRESS]. Review of AEs and changes in concomitant medications
[IP_ADDRESS]. Complete phy sical examination (urogenital/anorectal exams will be performed at 
the discretion of the Investigator) 
[IP_ADDRESS]. 12- lead ECG performed supi[INVESTIGATOR_050]
[IP_ADDRESS]. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
[IP_ADDRESS]. Urine collection for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis and urine chemistry
[IP_ADDRESS].2. Urine pregnancy  test (females of childbearing potential only); positive urine 
pregnancy  tests will be confirmed with a serum test
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page57 11 March [ZIP_CODE].[IP_ADDRESS]. Urine storage sample for possible additional clinical testing
[IP_ADDRESS].4. Evaluations of renaltubular function required if last test was acquired >12 weeks 
from the date of the ESDD Visit (collected fasted): I f the subject has not fasted 
prior to the visit, the visit may  proceed, but the subject must return within 
72hours in a fasted state to provide a urine sample for these evaluations
[IP_ADDRESS]. Blood sample collection for the following laboratory  analyses:
[IP_ADDRESS].1. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and 
indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid, and am ylase (reflex lipase testing is performed in subjects with total amy lase 
1.5ULN)
[IP_ADDRESS].2. Estimated GFR, according to the Cockcroft Gault formula for creatinine clearance
[IP_ADDRESS].3. Hematology  profile: complete blood count (CBC) with differential and platelet
count
[IP_ADDRESS].4. Plasma HIV -1 RNA
[IP_ADDRESS].5. CD4+ cell count
[IP_ADDRESS].6. Plasma storage samples f or virology , safetyand/or PKtesting 
[IP_ADDRESS].7. Serum storage sample for possible additional clinical testing 
(for subjects who 
provide consent)
[IP_ADDRESS].8. HIV-1 genotype/phenotype resistance testing for subjects with confirmed 
virologic rebound with HIV-1 RNA value ≥ 400 copi[INVESTIGATOR_014]/mL
[IP_ADDRESS].9. Evaluations of b one turnoverrequired if last test was acquired > 12 weeks from 
the date of the ESDD Visit (collected fasted): If the subject has not fasted prior to 
the visit, the visit may  proceed, but the subje ct must return within 72 hours in a 
fasted state to provide a blood sample for these evaluations
[IP_ADDRESS].10. Evaluations of inflammationrequired if last test was acquired > 12 weeks from 
the date of the ESDD Visit , including but not limited to cystatin-C,IL 6, hs CRP, 
d-dimer, sCD14, and sCD163
[IP_ADDRESS].[ADDRESS_893176] was acquired > 12 weeks from 
the date of the ESDD Visit , including but not limited to soluble gl ycoprotein VI 
(sGPVI), P -selectin, and soluble CD40 ligand
[IP_ADDRESS].12 Platelet function for substudy  subjects (onl y at selected sites)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page58 11 March [ZIP_CODE].4.1.7. DXA scan (spi[INVESTIGATOR_35632]) required if last scan was acquired > 12 weeks from the 
date of the ESDD Visit. DXA scan can occur up t o 10 days after the ESDD Visit
[IP_ADDRESS]. Drug accountability
6.4.2. 30 Day Follow -Up Visit
Subjects who complete the study  through the Unblinding Visit and who do not wish to receive 
the open-label F/TAF (including subjects in countries such as the [LOCATION_006]) will be required to return 
to the clinic [ADDRESS_893177] one subsequent visit after the Early Study Drug Discontinuatio n Visit 
will notbe 
required to complete the 30 -Day Follow -Up Visit.
For the purpose of scheduling a 30 -Day Follow-Up Visit, a  6 days window may  be used. The 
following evaluations are to be completed at the 30- Day Follow-Up Visit:
[IP_ADDRESS]. Review of AEs and changes in concomitant medications
[IP_ADDRESS]. Symptom-directed phy sical examination
[IP_ADDRESS]. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature) including 
weight 
[IP_ADDRESS]. Urine collection for the following laboratory  procedures:
[IP_ADDRESS].1. Urinalysis
[IP_ADDRESS].2. Urine pregnancy  test (females of childbearing potential only); positive urine 
pregnancy  tests will be confirmed with a serum test
[IP_ADDRESS].3. Urine storage sample for possible additional clinical testing
[IP_ADDRESS]. Blood sample 
collection for the following laboratory  analyses:
[IP_ADDRESS].1. Chemistry  profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and 
indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric 
acid, and am ylase (reflex lipase testing is performed in subjects with total amy lase 
1.5ULN)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page59 11 March [ZIP_CODE].[IP_ADDRESS]. Hematology  profile: complete blood count (CBC) with differential and platelet 
count
[IP_ADDRESS].3. Plasma HIV -1RNA
[IP_ADDRESS].4. CD4+ cell count
[IP_ADDRESS].5. Serum storage sample for possible additional clinical testing (for subjects who 
provide consent)
At the 30 Day  Follow Up Visit, any  evaluations showing abnormal results believed to be a 
reasonable possibility  of acausal relationship with the study  drug will be repeated weekl y (or as 
often as deemed prudent by  [CONTACT_737]) until the abnormality  is resolved, returns to 
baseline, or is otherwise explained.
6.5. Criteria for Discontinuation of Study Treatment
Study medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinicalstatus to a significant degree Following resolution of intercurrent illness, the subject 
may resume study dosing at the discretion of the investigator.
Unacceptable toxicity , or toxicity  that, in the judgment of the investigator, compromises the 
ability to continue study -specific procedures or is considered to not be in the subject’s best 
interest
Therapeutic failure 
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 5
Discontinuation of the study  at the request of [COMPANY_009], a regulatory  agency or an institutional 
review board or independent ethics committee (IRB/IEC)
6.6. Bone Mineral Density Evaluations
For all subjects excluding those in German y, dual energy x-ray absorptiometry  (DXA) scans will 
be performed prior to study  drug administration at the Day  1, every 24 weeks, Unblinding Visit 
and the Early Study Drug Discont inuation Visit (if applicable). Scans will cover the spi[INVESTIGATOR_662150] y.DXAscan results will be provided to study  
sites.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page60 11 March 2015A complete description of the procedures performed for the DXAscans will be provided in a 
DXAmanual.
6.7. Other Evaluations 
6.7.1. Markers of Bone Turnover
For all subjects, blood will be collected for selected evaluations of bone turnover, including 
C-type collagen sequence (CTX) and procollagen ty pe 1 N-terminal propeptide (P1NP)at Day1 
Visit, Weeks 4, 12, 24, 48, 72, 96 and ESDD (if applicable).
6.7.2. Markers of Renal Tubular Function
For all subjects, urine will be collected for selected evaluations of renal tubular function , 
including retinol binding protein and beta 2 microg lobulin at the Day  1 Visit, Weeks 4, 12, 24, 
48, 72, 96 and ESDD (if applicable).
6.7.3. Markers of Inflammation
For all subjects, blood will be collected at Day  1 Visit, Weeks 4, 12, 24, 48, 72, 96 and ESDD (if 
applicable) for selected evaluations of inflammati on, including but not limited to cystatin-C, IL 
6, hs CRP, d- dimer, sCD14, and sCD163.
6.7.4. Markers of Platelet Function
For all subjects, blood will be collected at Day  1 Visit, Weeks 4, 12, 24, 48, 72, 96 and ESDD (if 
applicable) for selected evaluations of p latelet function, including but not limited to soluble 
glycoprotein VI (sGPVI), P -selectin, and soluble CD40 ligand. In addition, a subset of subjects 
will be evaluated for the platelet function (see Section6.10). 
6.8. Blood and Urine Storage
From subjects who provide additional consent, a portion of the blood drawn at all visits (except 
the Screening Visit and Unscheduled Visits) will be frozen and stored. A portion of urine 
samples drawn from all subjects at all visits (except the Screening Visit and Unscheduled Visits) 
will be frozen and stored.These stored blood and urine samples may  be used by  [CONTACT_662168]-1or clinical laboratory  testing to provide additional safety
 data. No human genetic testing 
will be performed without expressed consent of study  subjects. At the conclusion of this study , 
these samples may  be retained in storage by  [CONTACT_10869], Inc. for a period up to 10 y ears.
6.9. Virologic Failure 
Subjects who experience virologic rebound (VR), as defined below, will be considered to have 
virologic failure.  
F/TAF
Protocol GS -US-311-[ADDRESS_893178] confirmed HIV -1 RNA 
≥ 50copi[INVESTIGATOR_014]/mL  (two consecutive tests) at a scheduled or unscheduled visit.
6.9.1. Management of Virologic Failure
If the viral load is ≥ 50 copi[INVESTIGATOR_014]/mL , HIV-1 RNA should be repeated at a scheduled or 
unscheduled visit ([ADDRESS_893179] with HIV -1 RNA 
≥ 50copi[INVESTIGATOR_014]/mL ).
Upon confirmation of HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL, potent ial causes of virologic failure 
should be documented.  Assessments should include:
—Adherence
— Concomitant medication
— Comorbidities (for example: active substance abuse, depression, other intercurrent 
illnesses)
If virologic failure is confirmed at the sch eduled or unscheduled visit and HIV -1 RNA value 
is ≥ 400 copi[INVESTIGATOR_014]/mL , the blood samples from the confirmation visit will be used for HIV -1 
genotype/phenotype testing.
If genotype/phenot ype resistance to study  drug is documented, study  drugs should be 
discontinued. 
If no resistance is detected from genot ype/phenot ype testing, subject may  remain on study  
drug and a repeat HIV -1 RNA should be repeated ([ADDRESS_893180] 
with viral load ≥ 50 copi[INVESTIGATOR_014]/mL ).  Investigators should carefully  evaluate the benefits and 
risks of remaining on study  drug for each individual subject and document this assessment in 
the on site medical record.  I nvestigators who opt to discontinue study  drugs for an individual 
subject must discuss with the Medical Monito r prior to study  drug discontinuation.
6.9.2. Subjects with ≥ 400 copi[INVESTIGATOR_014]/mL of HIV -1 in the Absence of VR
Subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL could subsequently  experience unconfirmed blips of 
HIV-1 RNA ≥ 400 copi[INVESTIGATOR_014]/mL . Such subjects will be anal yzed for resis tance if the unconfirmed 
rebound happens at Week 48, or at the last visit while receiving stud y drugs (or within 72 hours 
of discontinuation of study  treatment).
Please refer to Figure6-1for the management of subjects who meet the criteria for virologic 
failure.
FffAF 
Protocol GS-US-311-1717 Final 
[COMPANY_009] Sciences, Inc. Original 
Figure 6-1. Schema for Management of Virologic Failure 
Screening Treatment Period 30-Day Follow-up 
Day I 
~ 
At any visit, a rebound in HIV-1 RNA to:?; 50 copi[INVESTIGATOR_014]/mL 
I 
Unconfirmed 
v:h-ologic Retum for scheduled/unscheduled HIV-1 
rebound: remain Rl'JA and potential genotype/phenotype 
on current (2-4 weeks later) 
a regimen 
~ 
I Confirmed virologic 
rebound b I 
Remain on study , 
I HIV-1 genotype/phenotype c I 
... ... 
If no reve1·se transcripta se resistance If reverse transcriptase, protease, or 
detected, continue on study dmgs. integrase resistance detec.ted, 
Repeat HIV-[ADDRESS_893181] will remain on their cturent. regin1en. 
b If virologic rebotmd is confmned , and the HIV -1 RNA is :;:: 400 copi[INVESTIGATOR_014]/mL, the HIV -1 genotype and phenotype (reverse 
transcriptase , protease, and, if applicable , integrase resistance) will be analyzed. 
c Based on the results of the genotype /phenotype assays, the subject will remain on study dtugs or study dt·ugs will be 
discontinued. If genotypi[INVESTIGATOR_007] /phenotypi[INVESTIGATOR_662151], a new ARV regimen may be configured at the discretion of the 
Investigator. 
d If no resistanc.e detected, HIV-1 RNA will be repeated (2-4 weeks later). Investigator reviews study dtug 
c.ontinuation /disc.ontinuation options and discuss with Medical Monitor prior to study drug discontinuation 
e A new ARV regimen will be configured , at the Investigator's discretion, and the subject will remain in the study 
CONFIDENTIAL Page 62 11 March 2015 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page63 11 March [ZIP_CODE].10. Platelet Function Substudy
In a subset of patients, platelet function (i.e. reactivity ) will be assessed at Day 1 Visit,Weeks 4, 
12, and the Earl y Study Drug Discontinuation Visit (if applicable). The assay  to assess platelet 
function will measure platelet aggregation in response to agonist(s). 
In addition, the expression of certain platelet receptors (e.g. gl ycoprotein V I) may be assessed 
using flow cy tometry. The target sample size for the substudy  is up to 80 subjects. 
The results will not be provided to the study sites. 
A complete description of the procedure performed for the evaluation of plateletreactivity  will 
be provided in a separate laboratory manual. 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page64 11 March [ZIP_CODE]. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
Anadverse event (AE) is any  untoward medical occurrence in a clinical study subject 
administered a medicinal product,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may also include pre -or post-treatment complications that occur as a 
result of 
protocol specif iedprocedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such assurgery, endoscopy ,tooth extraction, andtransfusion.
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected beforethe 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (e.g. ,hospi[INVESTIGATOR_10800] , socialand/or convenience admissions)
Overdose withoutclinical sequelae (see Section7.6.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in w hich the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_1081]
Persistent or signific ant disability /incapacit y
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page65 11 March 2015A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_110080]. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency  room or at home for allergic bronchospasm; blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modifi cation, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and7.1.2.If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section7.6.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAE s for 
causality and severity , and for final review and confirmation of accuracy  of event
information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to IMP
therapy using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page66 11 March 2015It should be emphasized that ineffective treatment should not be considered as causal ly related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures, (eg.,venipuncture)
7.2.2. Assessment of Severity
Severity should be recorded and graded according to the GSI Grading Scale for Severit y of 
Adverse Event s and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may not be in agreement with the grading of 
the laboratory abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initia tion of study  medication, the following t ypes of events 
should be reported on the electronic case report form (eCRF): all SAEs and adverse events 
related to protocol -mandated procedures.
7.3.1. Adverse Events
Following initiation of study  medication, a ll AEs, re gardless of cause or relationship, until 
30days after last administration of study  IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
[COMPANY_009] Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
7.3.2. Serious 
Adverse Events 
All SAEs, regardless of cause o r relationship, that occurs after the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow-up period, must be reported to the 
eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
F/TAF
Protocol GS -US-311-[ADDRESS_893182] dose of study  IMP, regardless of caus ality, should also be reported. Investigators are not 
obligated to actively  seek SAEs after the protocol defined follow up period however, if the 
investigator learns of an y SAEs that occur after study  participation has concluded and the event 
is deemed relevant to the use of IMP, he/she should promptly  document and report the event to 
[COMPANY_009] DSPH.
All AEs and SAEs will berecorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for any reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record t he SAE on the paper serious adv erse event reporting 
form and submit within 24 hours to:
[COMPANY_009]Drug Safet y and 
Public Health (DSPH):Fax: +[PHONE_13693]
E-mail:[EMAIL_11049]
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a p aper form because the eCRF database has been locked, no 
further action is necessary. All AEs and SAEs will be recorded in the eCRF database within 
the timelines outlined in the eCRF completion guideline. 
For fatal or life -threatening events, copi[INVESTIGATOR_662152], autops y reports, and other 
documents are alsoto be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a docume nt to the subject i dentifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form.
7.4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page68 11 March 2015other country -specific legislation or regulations, [COMPANY_009] may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs) ,or 
suspected 
unexpected serious adverse reactions (S[LOCATION_003]Rs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify  worldwide regulatory  
agenciesand the relevant IECin concerned Member States of applicable S[LOCATION_003]Rs asoutlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_10855] i nvestigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notify ing them of relevant S[LOCATION_003]R reports associated 
with any study IMP. The investigator should notify  the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Special Situations Reports
7.5.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy  reports regardless of an 
associated AE.  
Medication error is any unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional and inappropriate useof a medicinal p roduct tha t is not in 
accordance with the protocol instructions or the local prescribing information .
An o
verdoseis defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the da ily dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of t he medicinal product.  
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page69 11 March [ZIP_CODE].5.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the stu dy, including the post study  drug follow -up 
period, to the [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware 
of the pregnancy . 
Refer to the eCRF completion guidelines for full instructions on the mechanism of pregnancy 
reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complic ations or other medical reasons) must be reported within [ADDRESS_893183] information is as follows: 
Email: [EMAIL_201]
Fax: +1 (650) 522 -
5477
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_893184] of situations that involve study  IMPand/or [COMPANY_009] concomitant 
medications, but do not apply to non-[COMPANY_009] concomitant medications. 
Special situations involving non-[COMPANY_009] concomitant medications doesnot need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form. 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page70 11 March 2015Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may be more appropriately  documented as a protocol deviation.
Refer to eCRF completion guidelines for full instructions on the mechanism of special situations 
reporting.
All clinical sequelae in relation to these special situation reports will be repo rted as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
7.6. Toxicity Management 
All clinical and clinicall y significant laboratorytoxicities will be managed according to uniform 
guidelines detailed in Appendix 3as outlined below.
All clinically  significant Grade [ADDRESS_893185]’s safety.
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the GSIGrading Scale for Severit y of Adverse Events and Laboratory Ab normalities 
(RefertoAppendix 4).
Any questions regarding toxicity  management should be directed to the Medical Monitor.
7.6.1. Grades [ADDRESS_893186] at the discretion of the Investigator.
7.6.2. Grades 3 Laboratory Abnormality or Clinical Event
For Grade [ADDRESS_893187].
For a Grade [ADDRESS_893188] should be withheld until t he toxicity  returns to Grade2.
If a laboratory  abnormality  recurs to Grade3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. Recurrence of laboratory  abnormalities considered 
unrelated to investigational medicinal product may not require permanent discontinuation.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page71 11 March [ZIP_CODE].6.3. Grade 4 Laboratory Abnormality or Clin ical Event
For a Grade [ADDRESS_893189] may  be continued without dose interruption for a clinically  
non-significant Grade3- 4 laboratory  abnormality  (e.g., CK elevation after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a Grade 3- [ADDRESS_893190] who has a 
DXAscan that demonstrates a decrease from baseline of > 5% in th e spi[INVESTIGATOR_184824] > 7% in the 
hip region be followed per local medical practice at the discretion of the investigator.
7.6.5. Management of Hyperbilirubinemia in Patients Receiving Atazanavir
Most patients taking atazanavir sulfate experience asy mptomatic elevations in indirect 
(unconjugated) bilirubin related to inhibition of UDP- glucuronyl transferase (UGT). 
As subjects on ATV -containing regimen are expected to have atazanavir-associated 
hyperbilirubinemia, occasionally  up to Grade 4 (> [ADDRESS_893191]), the management of graded 
laboratory  abnormality  described above in Section7.6is not applicable for the management of 
graded hyperbilirubinemia in these subjects . 
However, repeat testing should be done and alternative etiologies (e.g. acute hepatitis B or C) be 
sought in the following subjects:
1.In those with elevation in conjugated (direct) bilirubin > 1.5 x UL N (i.e. direct 
hyperbilirubinemia), regardless of the hyperbilirubinemia grade, liver labs (total bilirubin, 
direct bilirubin, AST, ALT) should be repeated within [ADDRESS_893192] bilirubin > 1.[ADDRESS_893193] or ALT abn ormalities should 
be managed according to Section7.6.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page72 11 March 2015Dose modification of atazanavir sulfate is not permitted. Subjects who experience unacceptable 
jaundice/scleral icterus due to atazanavir -associated hy perbilirubinemia can be discontinued 
from study  atthe discretion of the Investigator.
7.6.6. Management of Possible Abacavir Hypersensitivity Reaction
Abacavir should not be used in patients known to carry the HLA -B*5701 allele due to increased 
risk of hy persensitivity  reaction, unless no other therapeutic option is available based on the 
treatment history  and resistance testing.
In a clinical stud y, 3.4 % of subjects with a negative HLA -B*5701 status receiving abacavir 
developed a h ypersensitivity  reaction. Therefore, even in the absence of HLA-B*[ADDRESS_893194] fever and/or rash as 
part of the s yndrome. Other signs and s ymptoms may  include respi[INVESTIGATOR_579164] s ymptoms 
such as dyspnoea, sore throat, cough, and abnormal chest x -ray findings (predominantly  
infiltrates, which can be localized), gastrointestinal sy mptoms, such as nausea, vomiting, 
diarrhea, or abdominal pain, and may  lead to misdiagnosis of hy persensitivity  as respi[INVESTIGATOR_82212] (pneumonia, bronchitis, phary ngitis), or gastroenteritis. Other frequently  observed signs 
or symptoms of the hy persensitivity  reaction may  include lethargy  or malaise and 
musculoskeletal sy mptoms (my algia, rarely  myolysis, arthralgia). The sy mptoms related to this 
hypersensitivity  reaction worsen with continued therapy  and can be life -threatening. These 
symptoms usually  resolve upon discontinuation of abacavir.
Hypersensitivity  reaction sy mptoms usually  appear within the first six weeks of initiatio n of 
treatment with abacavir, although these reactions may  occur at any  time during therapy . Patients 
should be monitored closely , especiall y during the first two months of treatment with abacavir.
Regardless of their HLA -B*[ADDRESS_893195] 
be permanently  discontinu ed if hypersensitivity  cannot be ruled out, even when other diagnoses 
are possible (respi[INVESTIGATOR_96613], flu -like illness, gastroenteritis or reactions to other medicinal 
products) {[ZIP_CODE]}.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page73 11 March [ZIP_CODE].6.7. Management of Changes in Estimated Glomerular Filtration Rate
Estimated glomerular filtration rate (GFR), according to the Cockcroft Gault formula, will be 
followed post -baseline during the stud y. All subjects with estimated GFR < 50 mL /min must 
have serum creatinine and subject’s weight measured again within [ADDRESS_893196] has confirmed estimated GFR < 50 mL /min, the Medic al Monitor should be 
notified and discontinuation of investigational medicinal product should be discussed.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page74 11 March [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective is:
To evaluate the efficacy  of switching ABC/3TCto F/TAFversus maintaining ABC/3TC in 
HIV-1 infected subjects who are virologically  suppressed on regimens containing ABC/3TC 
as determined b y the proportion of subjects with HIV -1 RNA < 50copi[INVESTIGATOR_014]/mL  at Week 48 
The secondary  objectives are :
To evaluate the efficacy, safety and tolerability of two regimens through Week 48 and 
Week96
To evaluate the bone safety  of two regimens as determined by  [CONTACT_184900][INVESTIGATOR_506437] y (BMD) at Week 48 and Week 96
8.1.2. Primary Endpoint
The primary  endpoint is the proportion of subjects with HIV -1 RNA < 50copi[INVESTIGATOR_014]/mL  at Week 48 
as defined b y the FDA snapshot algorithm.
8.1.3. Secondary Endpoint
Secondary endpoints include:
The proportion of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Weeks 96 as defined by  [CONTACT_184921]
The percent change from baseline in hip
and spi[INVESTIGATOR_110075] 48 and Week 96
8.2. Analysis Conventions
8.2.1. Analysis Sets
[IP_ADDRESS]. All Randomized
The Randomized anal ysis set includes all subjects who are randomize d into the study . This is the 
primary analysis set for by -subject listings.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page75 11 March [ZIP_CODE].2.1.2. Efficacy
[IP_ADDRESS].1. Full Anal ysis Set (FAS)
The full anal ysis set (FAS) will include all subjects who (1) are randomized into the study  and 
(2)have received at least one dose of stud y medication. Subjects will be grouped according to 
the treatment to which they  were randomized.
[IP_ADDRESS].2. Per- Protocol (PP) Anal ysis Set
The Per-Protocol anal ysis set will include all subjects who (1) are randomized into the study , 
(2)have received at least one dose of study medication, and (3) have not committed any  major 
protocol violation, including the violation of key  entry criteria. Subjects will be grouped 
according to the treatment they  actually received.
[IP_ADDRESS]. Safety
[IP_ADDRESS].1. Full analysis Set (FAS)
The safety analysis set will include all randomized subjects who (1) are randomized into the 
study and (2) have received at least one dose of study  medication. All the data collected up to 
30days after subjects permanently  discontinue their study  regimen will be included in the saf ety 
summaries. Subjects will be grouped according to the treatment they  actually received.
[IP_ADDRESS]. DXA
[IP_ADDRESS].1. Hip DXA Anal ysis Set
The Hip DXA analysis set will include all subjects who were randomized and received at least 
onedose of stud y medication, and had no nmissing hip BMD value for the Day 1visit. Subjects 
will be grouped according to the treatment they  actually received.
[IP_ADDRESS].2. Spi[INVESTIGATOR_662153] y medication, and had nonmissing spi[INVESTIGATOR_662154] 1 visit. Subjects 
will be grouped according to the treatment they  actually received.
[IP_ADDRESS]. Pharmacokine tics
The Pharmacokinetic (PK) anal ysis set will include all subjects who are randomized and have 
received at least one dose of study  medication and for whom concentration data of any  analytes 
of interest is available. The PK anal ysis set will be used for analyses of general 
pharmacokinetics .
F/TAF
Protocol GS -US-311-[ADDRESS_893197] descriptive 
methods.
Demographic summaries will include sex, race/ethnicity ,and age.
Baseline data including body  weight, height, bod y mass index, HI V-1 infection, and enrollment 
distribution by  [CONTACT_10859] .
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  efficacy endpoint is the proportion of subjects with HIV- 1 RNA <
50copi[INVESTIGATOR_014]/mL at 
Week 48 as defined by [CONTACT_662169]. The primary  analysis of the efficacy  will be 
based on the full analy sis set (FAS).
The null hypothesis is that the proportion of subjects withHIV-1 RNA < 50copi[INVESTIGATOR_014]/mL 
(asdefined b y the FDA snapshot algorithm ) at Week [ADDRESS_893198] 
10percentage points lowerthan the response rate in the Treatment Arm2; the alternative 
hypothesis is that the response rate in Treatment Arm1 is less than 10% lowerthan that in 
Treatment Arm 2.  
Non-inferiority will be assessed using the conventional confidence interval approach. The point 
estimate of treatment differe nce (F/TAFarm –FTC/TDFarm) and the associated two- sided 95% 
confidence interval will be constructed using normal approximation method based on stratum -
stratified Mantel-Haenszel proportions, where the stratification factor is the third agents (boosted 
protease inhibitors vs. other agents). 
Once non -inferiority of F/TAFtreatment regimen to FTC/TDF treatment regimen is established, 
the lower bound of the 95% CI  will be compared to 0; if the lower bound of the 95% CI is 
greater than 0, then superiority  ofF/TAFover FTC/TDF will be established.
8.5.2. Secondary Analyses
The proportion of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 96, as defined b y the FDA 
snapshot algorithm, will be anal yzed using the same method as for the primary  efficacy endpoint.
8.6. Safety Analysis
All safety analyses will be performed using the safety  analysis set.
F/TAF
Protocol GS -US-311-[ADDRESS_893199]’s extent of exposure to IMPdata will be generated from the IMPadministration data. 
Exposure data will be summarized by  [CONTACT_1570].
Duration of exposure to IMP will be expressed as the number of weeks between the first and last 
dose of the stud y regimen, inclusive, regardless of temporary  interruptions in study  regimen 
administration and summarized by [CONTACT_3148]. 
Dosing information for individual subjects will be listed.
8.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT),and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event that begin son or 
after the date of first dose of 
IMPstudy regimen up to30days afterthe date of last dose of IMPstudy regimen or any  AEs 
leading to study regimen di scontinuation
Summaries (number and percentage of subjects) of treatment -
emergent adverse events (b y SOC 
and PT) will be provided by  [CONTACT_1570]. Additional summaries will include summaries for 
adverse events b y grade, Investigator’s assessment of rel ationship to I MP, and effect on IMP 
dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Category C events that are indicative of an AIDS- Defining Diagnoses. The [COMPANY_009] medical 
personnel will review the p ossible Category  C events and approve the events that meet the 
definition. Those events that do meet the Category C definition of an AIDS -Defining Diagnosis 
will be listed.
A listing of Category  C, AIDS -Defining Diagnosis, can be found in Appendix 6.
8.6.3. Laboratory Evaluations
Selected laboratory  data will be summarized using onl y observed data. Absolute values and 
changes from baseline at all scheduled visits will be summarized.
F/TAF
Protocol GS -US-311-[ADDRESS_893200] 
dose of study  regimen plus 30 day s, will be summarized by  [CONTACT_1570]. If baseline data are 
missing, then an y graded abnormality  (i.e. at least a Grade 1) will be considered treatment 
emergent. The maximum toxicity  grade will be summarized by  [CONTACT_10862].
Laboratory  abnormalities that occur before the first dose of study  regimen or after the subject has 
been discontinued from treatment plus [ADDRESS_893201] agent stratum ( boosted protease inhibitors vs. other agents ) 
as a fixed effect.
Missing 
post-baseline values for BMD will be imputed using last observation carried forward 
(LOCF).
8.6.5. Other Safety Evaluations
Safety ECGs will be summarized for subjects in the Safet y Analysis Set. Number and percent of 
subjects with abnormal safet y ECG will be summarized by [CONTACT_765].
8.7. Pharmacokinetic Analysis
The PK concentration data of individual anal ytes may be explored.
8.8. Analysis of Evaluation s of Bone Turnover, Renal Tubular Function, and 
Inflammation
The observed values and changes from baseline in the se evaluations will be summarized by  
[CONTACT_72082] , based on the safet y analysis set . The 
difference in change from baseline in these evaluations between two treatment arms will be 
tested using van Elteren method, stratified by  [CONTACT_662165] ( boosted protease inhibitors vs. 
other agents ).
The skewness of the data will be examined and a natural log transfo rmation may  be applied
especially for exploratory anal ysis. If any transformation is applied, the changes from baseline
will be reported in original units (ie, back transformation will be applied to the generated
statistics, eg: fold -change from baseline m ay be reported instead of change from baseline).
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page79 11 March [ZIP_CODE].9. Sample Size
A total of 500 HIV -1 infectedsubjects, randomized in a 1:1 ratio to two arms (250 subjects per 
arm), achieves at least 90% power to detect a non -inferiority  margin of 10% in Week 48 
response rate (HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL as defined by  [CONTACT_662169]) 
difference between the two groups. For sample size and power computation, it is assumed that 
both treatment arms have a response rate of 0.87, that a non- inferiority  margin is 0.10, a nd that 
the significance level of the test is at a one- sided 0.025 level.
8.10. Independent Data Monitoring Committee
An external multidisciplinary  data monitoring committee (DMC) will review the progress of the 
study and perform interim reviews of safet y data, and provide recommendation to [COMPANY_009] 
whether the nature, frequency , and severit y of adverse effects associated with study treatment 
warrant the early  termination of the study  in the best interests of the participants, whether the 
study should continue as p lanned,or the stud
y should continue with modifications. The DMC 
may also provide recommendations as needed regarding study  design, and the collection or 
analysis of data.
The DMC’s specific activities will be defined b y a mutually  agreed charter, which wi ll define the 
DMC’s membership, conduct and meeting schedule.
While the DMC will be asked to advise [COMPANY_009] regarding future conduct of the study , including 
possible earl y study termination, [COMPANY_009] retains final decision -making authority  on all aspects of 
the study.
An analysis for the Week [ADDRESS_893202] a prior intent to ask the IDMC to review Weeks 48 
results and to consider early  termination of the study even if there is early  evidence of favorable 
efficacy.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page80 11 March [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The Investigator will ensure that this stud y is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and South 
Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the count ry in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The Investiga tor will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators”, 21 CFR, 
part 50, “Protection of Human Subject”, and 21 CFR, part 56, “Institutional Review Board”.
The Investigator and all applicable Sub- Investigators will comply  with 21 CFR, Part 54, 
“Financial Disclosure b y Investigators”, providing documentation of their financial interest or 
arrangements with [COMPANY_009], or proprietary  interests in the invest igational drug under study . This 
documentation must be provided prior to the Investigator’s (and an y Sub-Investigator’s) 
participation in the study. The Investigator and Sub- Investigator agree to notify  [COMPANY_009] of an y 
change in reportable interests during the study and for [ADDRESS_893203] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of th e study used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator w ill submit to and receive documented approval from 
the IRB/IECany modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IECapproval, with the exception of those necessary  to 
reduce immediate risk to study subjects.
F/TAF
Protocol GS -US-311-[ADDRESS_893204] current IRB-or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  [CONTACT_662170]. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from u nauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code  will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB [or] IEC,or laboratory . Laboratory  
specimens must be labeled in such as way  as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions. NOTE:The 
investigator must keep a screening log showing codes, names, and a ddresses for all subjects 
screened and for all subjects enrolled in the trial. Subject data will be processed in accordance 
with all applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, eCRF , the IMP, and any other study  information, remain the 
sole and exclusive property  of [COMPANY_009] during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except empl oyees or agents directl y 
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stu dy site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, IRB 
[or] IECand governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page82 11 March 2015Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
Participation in study (including study number);
Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (includi ng dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality and severity);
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_893205] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, unt il 2years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified 
by [CONTACT_90282], by  [CONTACT_427], or by  [CONTACT_90283]. The 
investigator must notify  [COMPANY_009] before destro ying any clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, [COMPANY_009] must be notified in advance.
If the investigator cannot providefor this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and [COMPANY_009] to store 
these records securel y away fromthe site so that they  can be returned sealed to the investiga tor 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copi[INVESTIGATOR_662155].
F/TAF
Protocol GS -US-311-[ADDRESS_893206] visit to enable the sponsor to perform central monitoring of 
safety data.  Subsequent to data entry, a study  monitor will perform source data verification 
within the EDC sy stem.Original entries as well as any  changes to data fields will be stored in 
the audit trail of the s ystem.  Prior to database lock (or an y interim time points as described in the 
clinical data management plan), the investigator will use his/her log in credentials to confirm that 
the forms have been reviewed, and that the entries accuratel y reflect the information in the 
source documents. The eCRF capture the data required per the protocol schedule of events and 
procedures. System-generated or manual queries will be issued to the investigative site staff as 
data discrepancies are identified by  [CONTACT_110105], who routinely  review the 
data for completeness, correctn ess, and consistency. The site coordinator is responsible for 
responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updating the original entry, and providing the reason for the update (e.g. data entr y 
error).At the conclusion of the trial, [COMPANY_009] will provide the site with a read -only archive copy  
of the data entered b y that site. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7. Investigat ional Medicinal Product Accountability and Return
[COMPANY_009] recommends that used and unused IMP supplies be returned to the shippi[INVESTIGATOR_10803]. The stud y monitor will provide instructions for return. If 
return is not possible, 
the study monitor will evaluate each study  center’s IMPdisposal 
procedures and provide appropriate instruction for destruction of unused IMPsupplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
[COMPANY_009] QA , the site may  destroy used (empt yor partially  empty) and unused IMPsupplies in 
accordance with th atsite’s approved SOP. A cop y of the site’s approved 
SOP will be obtained 
for central files. 
If IMPis destroyed on site, the investig ator must maintain accurate records for all IMP
destroyed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion, copi[INVESTIGATOR_10804]. Another copy  will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]
’s appointed stud y monitors , to IRBs [or] IECs , or to regulatory  authority  or health 
authority inspectors.
F/TAF
Protocol GS -US-311-[ADDRESS_893207] submit a ll protocol modifica tions to the IRB [or] 
IECin accordance with local requirementsand receive documented IRB [or] IECapproval 
before modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulator y agency. [COMPANY_009] will 
ensure that the report meets the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases.
Investigators in this study  may communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study in their entiret y have been publicly disclosed b y or with the consent of 
[COMPANY_009] in an abstrac t, manuscript, or presentation form or the study  has been completed at all 
study sites for at least [ADDRESS_893208] 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings.  If req uired under the applicable statutory  
and regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
F/TAF
Protocol GS -US-311-[ADDRESS_893209] access to the 
investigator’s source documentation in order to verify  the accuracy of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRFat regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to n otify the [COMPANY_009] medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authority(ies), IRBs, and IECs. In terminating th e study, [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
F/TAF
Protocol GS -US-311-[ADDRESS_893210] s for 
activation of the a ntiviral agent 9- (2-phosphony lmethoxy ethyl)adenine in human 
lymphoid cells. Antimicrob Agents Chemother 1995;39 (10):2304 -8.
2202 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16:31 -41.
[ZIP_CODE] Schneider E, Whitmore S, Gly nn KM, Dominguez K, Mitsch A, McKenna MT. 
Revised surveillance case definitions for HIV infection among adults, 
adolescents, and children aged <18 months and for HIV infection and AIDS 
among children aged 18 months to <13 y ears--United State s, 2008. MMWR 
Recomm Rep 2008;57 (RR- 10):1-12.
[ZIP_CODE] Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, 
et al. Comparison of changes in bone density  and turnover with abacavir -
lamivudine versus tenofovir -emtricitabine in HIV -infected adults: [ADDRESS_893211] Dis 2010;51 (8):963-72.
[ZIP_CODE] DeJesus E, Rockstroh J, Henry  K, Molina J -M, Gathe J, Ramanathan S, et al. Co-
formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil 
fumarate versus ritonavir -
boosted atazanavir plus co- formulated emtricitabine and 
tenofovir disoproxil fumarate for initial treatment of HIV -1 infection: a 
randomised, double -blind, phase 3, non -inferiority  trial. Lancet 2012;379:2429 -
38.
[ZIP_CODE] Gallant JE, Stasz ewski S, Pozniak AL , DeJesus E, Suleiman JM, Miller MD, et al. 
Efficacy and safety of tenofovir DF vs stavudine in combination therap y in 
antiretroviral -naive patients: a 3 -year randomized trial. JAMA 2004;292 (2):191-
201.
[ZIP_CODE] McComsey  GA, Kitch D, Daar ES, Tierney  C, Jahed NC, Tebas P, et al. Bone 
mineral density  and fractures in antiretroviral -naive persons randomized to 
receive abacavir -lamivudine or tenofovir disoproxil fumarate- emtricitabine along 
with efavirenz or atazanavir -ritonavir: Aids Clinical Trials Group A5224s, a 
substudy of ACTG A5202. J I nfect Dis 2011;203 (12):1791 -801.
[ZIP_CODE] Ezzati M, L opez AD. Estimates of global mortality  attributable to smoking in 
2000. Lancet 2003;362 (9387):847-52.
[ZIP_CODE] [COMPANY_009] Sciences Inc. VI READ®(tenofovir disoproxil fumarate) tablets, for oral 
use VIREAD®(tenofovir disoproxil fumarate) powder, for oral use. U.S. 
Prescribing Information.  Foster City , CA. Revised October 2013:
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page87 11 March 201527071 Joint United Nations Programme on HIV/AIDS (UNAIDS). Global rep ort: 
UNAIDS report on the global AIDS epi[INVESTIGATOR_901].  2013.
[ZIP_CODE] Williams I , Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British 
HIV Association guidelines for the treatment of HIV-1- positive adults with 
antiretroviral therap y 2012 (Updated N ovember 2013. All changed text is cast in 
yellow highlight.). HIV Med 2014;[ADDRESS_893212] 1:1 -85.
[ZIP_CODE] Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 
(4):294-
301.
[ZIP_CODE] Department of Health and Human Services (DHHS). Guidelines for the Use of 
Antiretroviral Agents in HIV -1-Infected Adults and Adolescents. Developed by  
[CONTACT_662171] –A 
Working Group of the Office of AIDS Research Advisory  Council (OARAC). 
Available at: http://aidsin fo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 
Revised 13 November 2014.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page88 11 March 201511. APPENDICES
Appendix 1.Investigator Signature [CONTACT_10882] 2.Study Proce dures Table
Appendix 3.Management of Clinical and Laboratory Adverse Events
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Recommendations
Appendix 6.Definitions of HIV -1 Related Disease (CDC Guidelines)
FffAF 
Protocol GS-US-[ADDRESS_893213] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT 
A Phase 3b, Randomized , Double-Blind , Switch Study to Evaluate FffAF in HIV-1 Infected 
Subjects who are Virologically Suppressed on Regimens containing ABC/3TC 
GS-US-311-1717 Original Protocol : 11 March 2015 
This protocol has been approved by [CONTACT_10869], Inc. The following signature [CONTACT_10883]. 
Moupal Das, MD, MPH (Pnnted) 
Medical Monitor 
B/1 I ) O!f)l5 [COMPANY_003] 
INVESTIG ATOR STATEMENT 
I have read the protocol, including all appendices, and l agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_279395] 89 II March 2015 
F/TAF
Protocol GS -US-311-[ADDRESS_893214]-
Week96d
Unblinding 
Visitv30 Day 
Follow-upe4 8 12 24 36 48 60 72 84 96Every 
12Weeks ESDDf
Informed Consent X
Medical History X
Concomitant 
MedicationsX X X X X X X X X X X X X X X X
Adverse Events X X X X X X X X X X X X X X X X
Complete Physical 
ExamX X X X X X XgX X
Symptom -Directed 
Physical Examh X X X X X X X X
12-Lead ECG 
(performed supi[INVESTIGATOR_050])X X X XzX X
Vital Signs and 
WeightX X X X X X X X X X X X X X XyX
Height X
Urinalysis and 
Urine ChemistryX X X X X X X X X X X X X X XaaX
Urine Storage 
SampleX X X X X X X X X X X X X X X
Urine Pregnancy 
Testi X X X X X X X X X X X X X X X
F/TAF
Protocol GS -US-311-[ADDRESS_893215]-
Week96d
Unblinding 
Visitv30 Day 
Follow-upe4 8 12 24 36 48 60 72 84 96Every 
12Weeks ESDDf
Serum Pregnancy 
Testi X
Chemistry ProfilejX X X X X X X X X X X X X X X X
Metabolic 
Assessmentsk X X X X X XrX
Estimated GFRwX X X X X X X X X X X X X X X
Hematology 
Profilel X X X X X X X X X X X X X X X X
Plasma HIV- 1 
RNAx X X X X X X X X X X X X X X X X
CD4+ Cell Count X X X X X X X X X X X X X X X X
Plasma Sample 
Storagem X X X X X X X X X X X X X X
Serum Storage 
Samplem X X X X X X X X X X X X X X X
Whole Blood 
Storage Samplebb X
Whole Blood 
Sample for PBMCsXdd
HBV Serology X
F/TAF
Protocol GS -US-311-[ADDRESS_893216]-
Week96d
Unblinding 
Visitv30 Day 
Follow-upe4 8 12 24 36 48 60 72 84 96Every 
12Weeks ESDDf
HCVAbSerologynX
HIV-1 
Genotype/Phenotypeo Xo
Single PK SamplepX X X X
Post-dose PK 
Sampleq X X
Platelet substudy 
blood sampleXeeXeeXeeXee
DXA Scan (spi[INVESTIGATOR_050] 
& hip)s X X X X X XsX X
Evaluations of 
boneturnover,
renal tubular 
function, 
inflammation and 
platelet functiontX X X X X X X Xt
Randomization X
Study Drug 
Dispensation and 
AccountabilityX X X X X X X X X X X X XccXu
aEvaluations to be completed within 30days prior to Day 1 Visit.
bSubjects will be dispensed study drug on the Day 1 Visit; initiation of treatment with the study drug must take place within 24 hours after the Day 1 visit. F/TAF, ABC/3TC, 
placebo-to-match F/ TAF and placebo -to-match ABC/3TC will be provided by [CONTACT_1034]. 
cAll study visi ts are to be scheduled relative to the Day 1 Visit date. Visit windows are 2 days of the protocol specified date through Week 12, 6 days of the protocol 
specified date through Week 36, and all other study visits except Week 48 and Week 96. Weeks 48 and 96 visit windows are 6 weeks of the protocol specified date.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page93 11 March 2015dStudy visits are to be completed within 6days of the protocol-specified visit date unless otherwise specified.
e Only required for those subjects who do not wish to continue to participate af ter the Unblinding Visit , all subjects in countries such as the [LOCATION_006] ,or those subjects who 
permanently discontinue study drug and do not continue in the study through at least one subsequent visit after the Early Stu dy Drug Discontinuation Visit. For the p urpose of 
scheduling a 30 -Day Follow -Up Visit, a 6days window may be used.
fEarly Study Drug Discontinuation visit to occur within [ADDRESS_893217] discontinues study drug.
gComplete physical examination every 48 weeks (urogenital/anorectal exams will be performed at the discretion of the Investigator).
hSymptom -directed physical examination as needed.
i Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
jChemistry profile: alkaline phosphatase, AST, ALT,  total bilirubin, direct and indirect bilirubin, total protein, albumin,  CPK, bicarbonate, BUN, calcium, chloride, 
creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase  1.5ULN) At Day 
1, Weeks 24, 48, 72, 96, and every [ADDRESS_893218] week 96, analyses of glucose will be done as part of the fasting metabolic assessment s and not as part of the chemistry 
profile. 
k Metabolic Assessments: Fasting glucose and lipid panel (total ch olesterol, HDL, direct LDL, triglycerides). If the subject has not fasted prior to the visit, the visit may 
proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.
lCBC with differential and platel et count.
mPlasma storage samples for virology, safety, and/orpharmacokinetic analysis. Serum storage samples for possible additional clinical testing. 
n If the antibody test result is positive, HCV RNA test will be performed to confirm HCV viremia
oHIV-1 genotype/phenotype resistance testing only conducted for subjects with confirmed virologic failure with H IV-1 RNA value ≥ 400 copi[INVESTIGATOR_014]/mL. Subjects should be 
managed according to the Virologic Failure Schema (Section 6.9).HIV-1 genotype/phenotype sample collection to occur if subjects HIV-[ADDRESS_893219] -Wk 96 (can be performed ≤ 10 days before study visits), atUnblinding Visit and the ESDD visit (if the l ast scan was 
acquired > 12 weeks from the date of the ESDD Visit).
tBlood for selected evaluations of boneturnover, including C -type collagen sequence (CTX) and procollagen type 1 N -terminal propeptide (P1NP) ,  inflammation including 
cystatin-C, IL -6, hs-CRP, d-dimer, sCD14, and sCD163 , and platelet function including soluble glycoprotein VI (sGPVI), P -selectin, and soluble CD40 ligand will be 
collected. Urine for selected evaluations of renaltubular function , including retinol binding protein, and bet a-2-microglobulin, will be collected.  Required for ESDD visit if 
last test was > [ADDRESS_893220] return within 72 hours in a fasted state to draw blood for theseevaluations and provide a urine sample for these evaluations . 
u Drug accountability only; study drug will not be dispensed at this visit.
vAt the Unblinding Visit, subjects (except in certain countries such as [LOCATION_006]) will be gi ven the option to receive open-label F/TAF FDC and attend study visits every 12 weeks 
until it becomes commercially available, or until [COMPANY_009] Sciences terminates the study in that country .
wEstimated GFR according to the Cockcroft- Gault formula for creatinine clearance 
xIf the HIV -1 RNA value is ≥ 50 copi[INVESTIGATOR_014]/mL a retest should be collected at a sc heduled or unscheduled visit, [ADDRESS_893221] (except for screening 
and basel ine results).
yWeight only
F/TAF
Protocol GS -US-311-[ADDRESS_893222] week 96
aaUrinalysis only
bbSample collected at Day 1 visit is for virology assessments.
ccF/TAF will be provided to all subjects who would like to receive open -label F/TAF (except in certain countries such as [LOCATION_006]) . Study drug will not be provided to subjects who 
wish to discontinue participation at this visit.
ddSingle whole blood sample collection (Week4 only): PBMC sample processing will be performed by [CONTACT_42059]; TFV-DP concentrations in PBMCs will be 
determined.
eeSample only collected for platelet substudy subjects at selected sites .
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page95 11 March 2015Appendix 3. Management of Clinical and Laboratory Adverse Events
Grade 1 Grade 4 Grade 3 Grade 2
May continue 
dosing at the 
discretion of the 
investigatorRepeat lab to 
confirm toxicity 
gradeRepeat lab to 
confirm toxicity 
grade
If confirm ed and possibly and/or probably related to 
investigational m edicinal products:
1.Withhold investigational m edicinal products until Grade2
2.Restart all investigational medicinal products at full doseIf confirm ed and unrelated to 
investigational m edicinal products, 
dosing may continue at the 
discretion of the investigatorIf confirmed and 
possibly or probably 
related to 
investigational 
medicinal products,
discontinue 
investigational 
medicinal products
dosing permanently 
and follow at periodic 
intervals at least 
weekly until a return 
to baseline or is 
otherwise explained
If Grade 3 or 4recurrence that is confirm ed and possibly or 
probably related to investigational m edicinal products, 
discontinue all investigational m edicinal products dosing 
permanentlyIf Grade 3 or 4recurrence that is considered unrelated to 
investigational m edicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page96 11 March 2015Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Version: 18June2012
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0to10.9g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0g/dL
100 to 120g/L9.0 to 10.0g/dL
90 to 100g/L9.0g/dL
90g/L
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page97 11 March 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 7Days1000to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00to 1.30GI/L 0.75to 1.00 GI/L 0.50to0.75 GI/L 0.50 GI/L
Infant, 2 –7 Days 1250 to 1500/mm3
1.25to1.50 GI/L1000 to 1250/mm3
1.00to< 1.25 GI/L750 to 1000/mm3
0.75to< 1.00 GI/L750/mm3
< 0.75 GI/L
Infant, 1 Day 4000 to 5000/mm3
4.00to5.00 GI/L3000 to 4000/mm3
3.00to < 4.00 GI/L1500 to 3000/mm3
1.50to< 3.00 GI/L1500/mm3
< 1.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00GI/Lto 2.50GI/L 1.50to 2.00GI/L 1.00 to 1.50GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00to2.00g/L 0.75to 1.00g/L 0.50 to 0.75g/L 0.50g/L
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page98 11 March 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40mg/L 40 to 50mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.[ADDRESS_893223] >1.[ADDRESS_893224] >2.[ADDRESS_893225] >3.[ADDRESS_893226]
Activated Partial
Thromboplastin Time (APTT) 1.00to 1.66ULN 1.66to 2.33ULN 2.33to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0to15.0% 15.0to20.0% 20.0% 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page99 11 March 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to<LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia 146  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
146  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 3.0 to3.4 mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to3.4 mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Hyperkalemia 5.6 to 6.0 mEq/L 6.0 to 6.5 mEq/L 6.5 to 7.0 mEq/L 7.0 mEq/L
5.6 to 6.0 mmol/L 6.0 to 6.5 mmol/L 6.5 to 7.0 mmol/L 7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64mg/dL 40 to55mg/dL 30 to40mg/dL 30 mg/dL
3.03 to 3.58 mmol/L 2.20 to3.03mmol/L 1.64 to2.20mmol/L 1.64 mmol/L
Infant,1Month 50 to 54mg/dL
2.8 to 3.0 mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
7Days7.8 to 8.4  mg/dL 7.0 to7.8 mg/dL 6.1 to7.0mg/dL 6.1mg/dL
1.94 to 2.10 mmol/L 1.74 to1.94 mmol/L 1.51 to1.74 mmol/L 1.51mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page100 11 March 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL 1.5 to 2.0 mg/dL 1.0 to 1.5 mg/dL 1.0 mg/dL
0.63  to LLN mmol/L 0.47 to 0.63 mmol/L 0.31 to 0.47 mmol/L 0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to 3.5 mg/dL
0.96 to 1.12 mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to 4.5 mg/dL
1.12 to 1.46 mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page101 11 March 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia 1.5 mg/dL to LLN 1.0 to1.5 mg/dL 0.5 to1.0 mg/dL 0.5 mg/dL
87 μmol/L to LLN 57 to87 μmol/L 27 to57 μmol/L 27 μmol/L
Creatinine 1.50 to 2.00 mg/dL 2.00 to 3.00 mg/dL 3.00 to 6.00 mg/dL 6.00 mg/dL
133 to 177 μmol/L 177 to 265 μmol/L 265 to 530 μmol/L 530 μmol/L
Bicarbonate 16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL 750 to 1200 mg/dL 1200 mg/dL
5.64–8.47 mmol/L 8.47–13.55 mmol/L 13.55 mmol/L
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page102 11 March 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL
(Fasting)130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
Pediatric >2 to <18 years 110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
*Calcium should be corrected for albumin if albumin is < 4.0 g/dL
F/TAF
Protocol GS -US-311-[ADDRESS_893227] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin 3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page104 11 March 2015URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hematuria (Dipstick) 1 2 3-4+ NA
Hematuria (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to1999 mg/24 h >1999to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499to799 mg/m2/24 h >799to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratories, toxicity grades will only be assigned to Dipstick 
Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for the 
AE.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page105 11 March 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmi a 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140–159mmHg systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(e.g., malignant hypertension) 
OR Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(e.g., malignant hypertension) 
OR Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(e.g.,tamponade) OR Urgent 
intervention indicated
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page106 11 March 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secComplete AV block 
Pediatric [ADDRESS_893228] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Complete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, e.g.,Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, e.g.,Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated 
(e.g.,anticoagulation, lysis 
filter, invasive procedure) Deep vein thrombosis AND 
Intervention indicated ( e.g.,
anticoagulation, lysis filter, 
invasive procedure) Embolic event ( e.g.,
pulmonary embolism, life -
threatening thrombus) 
Vasovagal Epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page107 11 March 2015RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_10809] 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_696] f ailure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page108 11 March 2015SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
[CONTACT_10872] (for disabled 
adults)Thinning or patchy hair loss 
detectable by [CONTACT_10873] –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epi[INVESTIGATOR_7387] (TEN)
Hyperpi[INVESTIGATOR_10810] (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing i nability to 
perform usual social & 
functional activities NA
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page109 11 March 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [ e.g.,tube feeding or 
total parenteral nut rition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated ( e.g.,diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(e.g.,sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(e.g.,obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3stools 
over baseline/24 hrPersistent epi[INVESTIGATOR_10813] 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(e.g.,hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive r ehydration 
indicated OR Hypotensive 
shock
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page110 11 March 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Dysphagia-Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences ( e.g.,aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated ( e.g.,
IVfluids)Life-threatening consequences 
(e.g.,hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening consequences 
(e.g., sepsis, circulatory 
failure, hemorrhage)
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inabili ty to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(e.g.,perforation)
Vomiting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent epi[INVESTIGATOR_10815]-threatening consequences 
(e.g.,hypotensive shock)
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page111 11 March 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood ( e.g.,
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & funct ional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others ( e.g.,
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page112 11 March 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respi[INVESTIGATOR_10818] 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page113 11 March 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive ( e.g.,
status epi[INVESTIGATOR_7397]), or difficult 
to control ( e.g.,refractory 
epi[INVESTIGATOR_002])
Seizure: (pre- existing) 
For Worsening of Existing 
Epi[INVESTIGATOR_10819]-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality ( e.g.,
severity or focality) Seizures of any kind that are 
prolonged, repetitive ( e.g.,
status epi[INVESTIGATOR_7397]), or difficult 
to control ( e.g.,refractory 
epi[INVESTIGATOR_002])
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< [ADDRESS_893229] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with orwithout secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page114 11 March 2015MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t-score or z- score
–2.5 to –1.0 BMD t-score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z-score 
–2.5 to –1.0BMD z-score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page115 11 March 2015SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospi[INVESTIGATOR_059] (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [ e.g.,
tube feeding or total parent eral 
nutrition]
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page116 11 March 2015INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual
social & functional activitiesPain/tenderness causing inability 
to perform basic self -care 
function OR Hospi[INVESTIGATOR_059] 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment ( e.g.,upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment ( e.g.,
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page117 11 March 2015ENDOCRINE/METABOLIC
Grade1 Grade 2 Grade 3 Grade 4
Lipodystrophy ( e.g.,back 
of neck, breasts, 
abdomen)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10875][INVESTIGATOR_10820]-threatening consequences 
(e.g.,ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10876] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual socia l & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(e.g., thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(e.g.,myxedema coma)
Lipoatrophy ( e.g.,fat loss 
from the face, extremities, 
buttocks)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_236726]
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page118 11 March 2015GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by [CONTACT_10878] -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction ( e.g.,stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional act ivitiesSystemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences ( e.g.,septic 
shock)
F/TAF
Protocol GS -US-311-[ADDRESS_893230] be excluded before the start of treatment with study drug and prevented thereafter by 
[CONTACT_199625]. Pregnancy testswillbe
performed regularly throughout this
study(Refer to Appendix 2). If females are using hormonal agents for contraception, the safe ty 
and/orefficacymaybe affected by [CONTACT_662172]-drug interaction. However, if females are using 
hormonal agents for contraception, the ho rmonal agent may  be contin
ued and a non -hormonal 
method (or methods) must be used concurrentl y.  If females utilize hormonal agents as one of 
their contraceptive methods, it is required that the same hormonal method be used for at least [ADDRESS_893231] version of the Investigator’s Brochure for additional information.
Additional pregnancy  precaution requirements may  be indicated based on third agent selection 
(refer to the relevant local label) and should be impleme nted at the discretion of the investigator.
2.Definition of Female of Childbearing Potential
For the purposes of this study
, a female subject of childbearing potential is a non- menopausal 
female who has not had a hysterectom y, bilateral oophorecto my, or medically documented 
ovarian failure.
A female subject may be considered menopausa l in eitherof the following conditions:
Surgical menopause: Appropriate medical documentation of prior complete bilateral 
oophorectom
y(i.e., surgical removal of the ovaries and occurring at the age at which the 
procedure was performed)
Ifage >54 years and with cessation for ≥12 months of previously occurring menses due to 
ovarian failure.
Women ≤ [ADDRESS_893232] 
agree to utilize protocol specified methods of contraception from the Screening/enrollment visit 
(for females) or first dose visit (for males) andfor30 days following the last dose of study drug. 
Female stu dy subjects who are not heterosexually activemust provide periodic confirmation of 
continued abstinence from heterosexual intercourse and regular pregnancy testing while taking 
studymedication. The Investigator will counsel subjects on the protocol specified method(s) for 
F/TAF
Protocol GS -US-311-[ADDRESS_893233] chooses to engage in heterosexual intercourse.  These 
methods are recommended due to the low failure rate ( i.e., less than 1% per year).
Protocol specified contraceptive methods are as follows: (1) a combination of one hormonal 
method and one barrier method; (2) use of an intrauterine device (IUD) or tubal sterilization ( Se
e
Appendix Table1below) or (3) complete abstinence from intercourse. Periodic abstinence from 
intercourse (for example: calendar, ovulation, s ymptothermal, post -ovulation methods) is not 
permitted.
Acceptable hormonal methods include injectable progesterone, progesterone implants, 
combination oral contraceptives, transdermal contraceptive patch, and vaginal ring. Acceptable 
barrier methods include diaphragm, cervical cap , and the male condom. Female subjects must 
use either a hormonal method or a barrier method if the partner has a vasectom y. If a subject has
undergone tubal sterilization or has had a Copper T 380A IUD or LNg 20 IUD inserted, no other 
contraception is nee ded; 
If tubal sterilization is via theEssure procedure, verification of tubal blockage by 
[CONTACT_31084][INVESTIGATOR_8913] (HSP) must be performed approximately [ADDRESS_893234] dose of stud y 
drug.
Appendix Table1.Protocol Specified Contraceptive Methods
MethodstoUseby[CONTACT_662173]
(chooseone andusewitha barrier
method)BarrierMethods
(chooseone andusewith a horm one 
method)
Intrauterine Devices(IUDs)
CopperT 380AIUD
LNg20IUD
TubalSterilizationEstrogen andProgesterone
Oralcontraceptives
Transdermal patch
Vaginalring
Progesterone
Injection
ImplantDiaphragm
   OR
Cervicalcap
Malecondom(without 
spermicide)
Partner’s vasectomy mustbeusedwitha hormone orbarriermethod.
The Investigator will counsel all subjects on the most effective method(s) for avoiding pregnancy  
during the stud y.
F/TAF
Protocol GS -US-311-[ADDRESS_893235] dose 
of study medication.
Use of condoms (except for lambskin) has been proven to decrease the risk of transmission of 
HIV and other sexually  transmitted diseases. The use of spermicide is not recommended if the 
subject or subject’s partner is infected with HIV.
4. Procedures to be Followed in the Event of Pregnancy
Female subjects will be instructed to notify theInvestigator iftheybecome pregnant at an ytime 
during the study, oriftheybecome pregnant within [ADDRESS_893236] report the 
information to the investigator and seek the investigator’s advice regarding action required with 
thestudydrug immediatel y.
Instructions for reporting pregnancy and pregnancy outcome are outlined in Section7.5.2.
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc . Original
CONFIDENTIAL Page122 11 March 2015Appendix 6. Definitions of HIV -1 Related Disease (CDC Guidelines)
Category B: Symptomatic Conditions in HIV-Infected Subjects
Bacillary angiomatosis
Candidiasis, orophary ngeal (thrush)
Candidiasis, vulvovaginal; persistent, frequent, or poorly  responsive to therapy
Cervical d ysplasia (moderate or severe)/cervical carcinoma in situ
Constitutional sy mptoms, su
ch as fever (38.5C) or diarrhea lasting  1month
Hairy leukoplakia, oral
Herpes zoster (shingles), involving at least two distinct epi[INVESTIGATOR_662156]
Idiopathic thrombocy topenic purpura
Listeriosis
Pelvic inflammatory  disease, particularl y if complicated b y tubo-ovarian abscess
Peripheral neuropath y
Category C: AIDS -Defining Diagnoses
Candidiasis of bronchi, trachea, or lungs
Candidiasis, esophageal
Cervical cancer, invasive
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal ( 1month duration)
Cytomegalovirus disease (other than liver, spleen or nodes)
Cytomegalovirus retinitis (with loss of vision)
Encephalopath y, HIV-related
F/TAF
Protocol GS -US-311-1717 Final
[COMPANY_009] Sciences, Inc . Original
CONFIDENTIAL Page123 11 March 2015Herpes simplex: chronic ulcer(s) (1month duration); or bronchitis, pneumonitis or 
esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal ( 1month duration)
Kaposi’s sarcoma
Lymphoma, Burkitt’s (or equivalent term)
Lymphoma, immunoblastic (or equivalent term)
Lymphoma, primary , of brain
Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary
Mycobacterium tuberculosis , pulmonary  or extrapulmonary  
Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
Pneumocy stis jirovecii pneumonia
Pneumonia, recurrent
Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain
Wasting sy ndrome attributed to HIV infection
CDC surveillance case definitions for HIV infection and AIDS -2008 { [ZIP_CODE]}